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Abstract 
Females are twice more likely to develop anxiety disorders as males. One mechanism 
believed to underlie the development and maintenance of anxiety disorders is 
impaired fear extinction. Recent studies have considered menstrual phase as a factor 
that distinguishes males from females in fear extinction recall. The aim of the study 
was to replicate previous findings and investigate the independent effects of estrogen 
and progesterone on fear extinction recall. Sixteen males and 29 females (13 in the 
early-follicular phase, 16 in the mid-luteal phase) were tested in a two-day fear 
acquisition and extinction task and provided a saliva sample to assess hormonal 
levels. Skin conductance response was used as the dependent variable in the fear 
acquisition task. No significant differences were found between mid-luteal females, 
early follicular females and males during fear acquisition and extinction learning 
however, early follicular females demonstrated significantly lower fear extinction 
recall (higher fear recovery) than mid-luteal females. The findings suggest that the 
mid-luteal phase, with high estrogen and progesterone, may facilitate fear extinction 
recall in females. This outcome supports the delivery of treatments for some anxiety 
disorders based on fear extinction, such as exposure therapy, to female clients during 
the mid-luteal phase of the menstrual cycle. 
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Fear is a natural response that facilitates safety-seeking behaviour when there 
is an immediate threat of actual or perceived danger, through arousal of the 
sympathetic system leading to the activation of the fight or flight response (Dias, 
Goodman, & Ressler, 2013; VanElzakker, Dahlgren, Davis, Dubois, & Shin, 2014). 
The fear response is associated with signs that the body is preparing for action, 
including tachycardia, tachypnoea, dry mouth, and sweating (Sandin et al., 2015; 
VanElzakker et al., 2014). These symptoms dissipate rapidly once threat or danger 
has disappeared, in a process known as fear extinction (Dias et al.). While symptoms 
of anxiety mirror those of fear, anxiety disorders are characterised by symptoms 
arising in the presence of non-threatening stimuli (Dias et al.; Graham & Milad, 
2011). In addition, unlike a natural fear response, pathological anxiety reflects a 
persistent and disabling increase in arousal and hypervigilance toward both external 
stimuli and internal sensations which leads to maladaptive behaviours such as 
avoidance (Dias et al.; Duits et al., 2015). Sandin et al. argue that it is the cognitive 
appraisal of events, behaviours, and bodily sensations that becomes distorted and 
accentuates the catastrophic thinking typical of anxiety disorders. Moreover, 
VanElzakker et al. suggest that malfunction in fear extinction may be an underlying 
factor leading to the onset of anxiety disorders.  
Epidemiological studies consistently reveal that females are twice as likely to 
develop anxiety disorders compared to males (e.g., Kessler et al., 2005). 
Furthermore, a recent meta-analysis conducted by Steel et al. (2014) found the global 
lifetime prevalence of anxiety disorders was higher for females than males. 
Importantly, although the prevalence of anxiety disorders is lower in non-western 
cultures, gender effects remain prominent cross-culturally (Steel et al.). Given that 
males have a higher frequency of exposure to fear-evoking events (e.g., war, 
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violence) than females it appears counter-intuitive that females render higher 
prevalence rates of anxiety disorders (Breslau et al., 1998). Nevertheless, females 
report higher anxiety symptom severity and disability (Lonsdorf et al., 2015). Kelly 
and Forsyth (2007) propose biological effects may exist that inform the observed sex 
differences. Taking into account the view that impaired fear extinction may underlie 
the development and maintenance of anxiety disorders, this study aims to investigate 
the effect of menstrual phase (with varying levels of estrogen and progesterone) on 
fear acquisition, extinction learning, and extinction recall in males and females.  
Fear Acquisition and Extinction 
A simple yet effective way of studying anxiety related psychopathology is to 
use a basic fear acquisition and extinction task (Lonsdorf et al., 2015), as illustrated 
in Figure 1. Initially the two neutral stimuli (here, pink and blue crosses) are 
presented on their own (habituation). During acquisition one of the two neutral 
stimuli is paired with an unpleasant, unconditioned stimulus (US) such as an 
electrical stimulus (Stockhorst & Antov, 2016). After numerous pairings of the 
neutral stimulus with the US, the neutral stimulus becomes a conditioned stimulus 
(CS
+
) and a fear response becomes a conditioned response (CR) to the CS
+
 (Kelly & 
Forsyth, 2007; Stockhorst & Antov). The other neutral stimulus, referred to as the 
CS
- 
, denotes a safety
 
signal as it is never paired with the electrical stimulus (Duits et 
al., 2015; Stockhorst & Antov). Subsequently, the presentation of the CS
+
 elicits the 
CR in the absence of the US, due to heightened expectancy of the aversive stimulus 
and fear associated with the CS
+ 
(Stockhorst & Antov).  In the early and late fear 
extinction phases, the CS
+
 and CS 
- 
are presented multiple times without the US, 
leading to a diminished CR in response to the CS
+
 (Zorawski et al., 2005). Then, as 
shown in Figure 2, extinction learning recall is tested approximately 24 hours later.  
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This encompasses measuring the memory of fear extinction learning, which occurred 
the day before by presenting multiple trials of the CS
+
 and CS 
–
 stimuli without the 
aversive stimulus (Graham & Milad, 2011). 
 
 
 
 
 
 
  
Figure 1.  A typical fear acquisition and extinction paradigm with CS
+
 and CS
- 
trials 
on day one. 
 
 
 
 
 
 
  
 
 
Figure 2. Fear extinction recall phase on day two of a fear acquisition and extinction 
paradigm with CS
+
 and CS
- 
trials. 
 To determine whether fear acquisition and extinction have taken place, the 
skin conductance response (SCR) has been used as an objective measure of 
sympathetic arousal to the presentation of CS
+
 and CS
- 
stimuli. SCR is an indicator 
of increased electrical connectivity that occurs in the skin as a consequence of 
physiological arousal (Critchley, Elliot, Mathias, & Dolan, 2000). Higher SCR 
indicates higher sympathetic response (e.g. fear response) and lower SCR indicates 
CS
+ 
8 
 
CS
- 
8 
 
 
CS - 8 
CS
+ 
5 
 
CS
- 
5 
 
 
CS - 4 
CS
+ 
5 
 
CS
- 
5 
 
 
CS - 4 
CS
+ 
4 
 
CS
- 
4 
 
 Habituation 
CS
+ 
5 
 
CS
- 
5 
 
 
CS - 4 
CS
+ 
5 
 
CS
- 
5 
 
 
CS - 4 
CS
+ 
8 
 
CS
- 
8 
 
 
CS - 4 
Early 
Extinction 
Recall 
Late 
Extinction 
Recall 
 
CS
+ 
5 
 
CS
- 
5 
 
 
CS - 4 
Early 
Extinction 
Late 
Extinction 
Acquisition 
5 
 
 
 
lower sympathetic response (e.g. no fear response) (Kelly & Forsyth, 2007; Bach & 
Friston, 2013). That is, SCR offers an objective, physiological insight into an 
individual’s subjective response to the feared stimulus (Vansteenwegen et al., 2005). 
As illustrated in Figure 3, SCR amplitude (indexed as baseline in habituation) rises 
shortly after fear acquisition begins. Typically, with numerous pairings of the CS
+
 
with an aversive stimulus, SCR with the CS
+ 
escalates and remains higher than that 
of the CS
-
, even in the absence of the US. High SCR in CS
+
 trials indicates the 
expectation of danger and lower SCR in CS- trials indicates the identification of 
safety (White & Graham, 2016). Extinction learning and extinction recall is marked 
by SCR amplitude returning to near-baseline levels (Vansteenwegen et al.; Otto, 
Moshier, & Kinner, 2014). SCR amplitude that remains significantly higher than baseline is 
indicative of poor fear extinction and poor extinction recall (Vansteenwegen et al.).  
  
 
 
 
 
 
Figure 3: An example of SCR amplitude to the CS 
+ 
and CS 
- 
in a two–day fear 
conditioning and extinction paradigm (adapted from Homberg, 2012). 
 While respecting ethical constraints to inducing fear acquisition (such as the 
imperative to reduce potential harm), conducting fear acquisition and extinction tasks 
within a laboratory setting enables researchers to closely examine the processes of 
fear acquisition and fear extinction (Jackson, Payne, Nadel, & Jacobs, 2005; 
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Wegerer, Kerschbaum, Blechert, & Wilhelm, 2014). Furthermore, whilst using a fear 
acquisition paradigm does not replicate the exact conditions under which fear 
acquisition takes place in the ‘real world’, eliciting a fear response adds emotional 
properties to the conditioned stimulus and thus provokes ‘real life’ symptoms 
(Miskovic & Keil, 2012). In addition, the paradigm affords the examination of 
associated learning and development of threat expectancy as a consequence of that 
associated learning (Duits et al., 2015). Obtaining SCR and subjective threat-
expectancy ratings from participants, allows direct observation of normal and 
dysfunctional fear extinction as well as extinction memory within a controlled 
environment (Graham & Milad, 2011; Miskovic & Keil; Wegerer et al.; Zorawski et 
al., 2005). 
Sex Differences in Fear Acquisition and Extinction 
 Early investigations of sex differences in fear extinction and recall yielded 
inconsistent findings. Some studies found that males demonstrated greater fear 
acquisition (higher SCR) versus females while other studies found the direct opposite 
(Guimareas, Hellerwell, Hensman,Wang, & Deakin, 1991; Inslicht et al., 2013; 
Milad et al., 2010; Zorawski et al., 2005). In addition to varying fear acquisition 
effects, there have been inconsistent findings in extinction recall between males and 
females (Lonsdorf et al, 2015; Milad et al., 2006). For example, Shevil et al. (2014) 
studied fear acquisition and recall in trauma exposed and PTSD-diagnosed males and 
females. Conducting a fear acquisition and extinction task the authors found males 
had greater fear extinction recall compared to females. In contrast, studying healthy 
male and female participants, Milad et al. (2006) found that females exhibited greater 
fear extinction recall compared to males. Dissimilarly, Lebron-Milad et al. (2012), 
who also studied healthy males and females, found no significant differences in fear 
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extinction recall between males and females. The variability in research outcomes in 
both clinical and healthy participants has consistently pointed to one potential 
explanation for these inconsistent findings as a failure to control for menstrual phase 
in females (Milad & Maeng, 2015; Shevil et al.). 
The Human Menstrual Cycle 
 The human menstrual phase is divided into two phases, based on estrogen and 
progesterone hormone levels, with the average menstrual cycle typically lasting 28 
days (Figure 4; Nillini, Toufexis & Rohan, 2011). The follicular (early and late) 
phase occurs between days one and 14 of the menstrual cycle (Wilson, Carvalho, 
Granot, & Landau, 2013). During the early follicular (days 1-7), estrogen and 
progesterone levels are both low, whereas in the late follicular (days 7 to 14) 
progesterone levels remain low while estrogen levels rise and peak (Graham & 
Milad, 2013). In the luteal phase (days 16 - 28), while estrogen remains higher than 
in the early follicular phase, it is dominated by elevated progesterone (Wilson et al.).  
During days 18 to 24, termed the mid-luteal phase, there is a peak in progesterone 
levels followed by the late luteal phase (days 24-28) when both estrogen and 
progesterone decline (Wilson et al., 2013). Females tend to report notably more 
symptoms of anxiety during episodes of low estrogen (pre-menstruation, 
menstruation, menopause, and postpartum; Glover et al., 2013).  According to 
Graham and Milad, differences in fear extinction recall observed between males and 
females may arise from fluctuating sex hormones. Furthermore, the divergence of 
estrogen seen in females over the menstrual cycle may offer an explanation for the 
observation of varying extinction recall in females (Milad et al. 2006). 
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Figure 4: Varying estrogen and progesterone levels across the follicular and luteal 
phases in the human menstrual cycle (taken from Otsuka Pharmaceuticals, 2016).  
The Impact of Menstrual Phase on Fear Acquisition, Extinction Learning and 
Extinction Recall 
 Milad et al. (2010) studied fear extinction and extinction recall in 18 healthy 
males and 36 healthy females not using hormonal contraception. A blood sample 
from each participant was drawn for rigorous measurement of estrogen and 
progesterone levels, in order to accurately assess sex hormone influence on fear 
acquisition, extinction learning, and extinction recall (Jackson et al., 2005).  Based 
on the pathology results, females were subsequently separated into two groups, early 
follicular (18 cases) and late follicular (18 cases). All participants underwent a two-
day fear acquisition and extinction paradigm. Coloured lights were used as the CS
+ 
and CS
-
, an electrical stimulus was the US, and SCR was the measured throughout 
the paradigm. In addition, to assess extinction recall (memory of fear extinction) on 
day two, a fear retention index (a measure of the recovered fear response to a CS
+
 
presented post-extinction learning) was calculated for each participant. The largest 
CS
+ 
SCR during conditioning was divided by the mean SCR of the first two trials 
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during extinction recall, and multiplied by 100 (Milad et al.). Overall, no significant 
differences were found in fear acquisition or extinction between the early follicular 
and late follicular females. When the data on females were pooled, males had 
significantly higher SCR during fear acquisition compared to females, suggesting 
males experienced greater conditioning effects. Nevertheless, there was no 
significant difference between males and females in the fear retention index (Milad 
et al).  However, when the fear retention index was analysed by group (males, early 
follicular females, and late follicular females), the early follicular females 
demonstrated significantly higher fear retention, signifying greater fear response to 
CS
+ 
stimuli, compared to late follicular females and males. While these results imply 
that estrogen facilitates fear extinction recall (Milad et al), the study did not include 
females in the mid-luteal phase, which limits the assessment of extinction recall 
across menstrual phase.  
 Extending this research, Graham and Milad (2013) conducted a study 
predicting that females with high estrogen levels would exhibit better fear extinction 
recall compared to females with low estrogen levels. Participants were 13 females on 
chemical contraception and 32 naturally-cycling females (blood serum results 
determined 16 low estrogen females; 16 high estrogen females) who completed a 
two-day fear acquisition and extinction task. Here, the CS
+ 
constituted pictures of 
lamps paired with an electrical stimulus. On day one, there were no significant 
differences in SCRs in acquisition and extinction learning across groups (Graham & 
Milad). On day two, a fear retention index (measuring fear recovery in extinction 
recall) was calculated by taking the mean SCR for all extinction recall trials and 
dividing it by the highest CS
+
 SCR in the conditioning phase, and multiplying by 100 
(higher percentage indicates poorer extinction recall; Graham & Milad; Milad et al, 
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2010). Analysis found that females with low estrogen and females on chemical 
contraception (chronically low estrogen) had higher fear retention indices, reflecting 
impaired fear extinction recall, compared to females with high estrogen. This 
suggests that low estrogen levels impair extinction learning recall (Milad & 
Graham). Furthermore, accumulating evidence suggests that the activation of a fear 
response enables rapid adaptation to the presence of threat (experimental acquisition) 
and the rapid extinction of fear responses (decreased SCR to CS
+ 
stimuli within 
session) during early and late experimental extinction, facilitates fear extinction 
learning (Stockhorst & Antov, 2016). However, as poor extinction recall is indexed 
by an elevation in fear recovery when original threat-conditioned stimuli (CS
+
 and 
CS
- 
stimuli without the aversive stimulus) are seen again (usually 24 hours later), it is 
the failure of extinction learning memory that may lead to psychopathological 
symptoms of anxiety (Lonsdorf et al., 2015). 
 Following on from the above study, Graham and Milad (2013) further 
explored estrogen as an important factor in fear extinction in 31 naturally-cycling 
females with low estrogen levels. The fear conditioning task differed from the typical 
paradigm, being conducted over three days to assess recall over a longer period than 
the traditional 24 hours. Day one comprised fear acquisition, day two covered fear 
extinction training, and extinction recall was assessed on day three.  On day one, 
participants completed the acquisition tasks. On day two, the participants were 
randomly assigned to a placebo or oral estradiol administered group prior to 
completing the extinction training. Analysis of SCR data found no significant 
differences in fear extinction between the two groups. On day three, the fear 
retention index was calculated. Analysis revealed that females receiving placebo 
demonstrated significantly higher scores on the fear retention index (calculations 
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explained above) than the estrogen-treated group (Graham & Milad). The authors 
concluded that estrogen facilitates the consolidation of extinction memory, in line 
with previous evidence (Graham & Milad). Moreover, with a wealth of evidence 
supporting progesterone in memory consolidation it is surprising that the possible 
effects of progesterone weren’t explored in this study (Maeng & Milad, 2015). 
 Wegerer et al. (2014) addressed the roles of estrogen and progesterone in fear 
acquisition and extinction, and intrusive memories, with an emphasis on the effects 
of hormonal levels over menstrual phase.  Naturally-cycling healthy females were 
recruited.  Eighteen females in the early follicular phase were tested between days 
one and seven of their menstrual cycle, and 21 females in the luteal phase were tested 
approximately five days before menstruation was due to commence. Before 
commencing the experiment, participants provided a saliva sample to measure 
hormonal levels. The fear acquisition and extinction task exposed participants to 
either an auditory stimulus paired with a violent video as the CS
+ 
or an auditory 
stimulus alone as CS
-
.  In addition, participants completed an online intrusive-
memory questionnaire once they had left the laboratory and for two days thereafter 
(prior to going to bed). Differences in SCR were obtained by subtracting the SCR in 
CS 
– 
trials from the SCR in CS
+
 trials. ANOVAs found no significant differences 
between the early follicular and luteal females in either habituation or fear 
acquisition, but significantly higher differential SCR was noted in the early follicular 
females during the extinction phase (directly after acquisition) compared to luteal 
females. Correlation analysis found early follicular females experienced significantly 
higher intrusive memory strength (evaluated by distress, frequency, and duration of 
memories) than luteal females. The study’s conclusions were that estrogen facilitates 
extinction learning and that low estrogen may elevate the prevalence of intrusive 
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memories.  It is interesting that, despite the authors’ emphasis on determining 
hormonal influences on fear-related responses (SCR), they did not include an 
additional day to further examine how estrogen and progesterone affect extinction 
recall. Moreover, the study included females in the late luteal stage when both 
progesterone and estrogen decline, i.e. progesterone is not at its peak, meaning that 
fear extinction effects between estrogen and progesterone could not be accurately 
discriminated (Nillini, Toufexis & Rohan, 2011).  
 Contributing to this line of research, White and Graham (2016) recently 
studied fear acquisition, extinction, and extinction recall, as well as the relationship 
between threat expectancy and SCR response. Participants were males, females using 
contraception (chronically low in estrogen), and naturally-cycling females. All 
participants completed a two-day fear acquisition and extinction task, whereby the 
CS
+
 was paired with an electrical stimulus during the acquisition phase (day one). On 
day two, the fear retention index was calculated as per Milad and Graham (2013). 
Blood serum analyses of estrogen and progesterone saw naturally-cycling females 
allocated to a high-estrogen high-progesterone or low-estrogen-low progesterone 
group. A regression analysis rendered estrogen as a significant predictor of extinction 
recall, with no significant variance explained by progesterone. Moreover, 
progesterone levels were not significantly different between the low estrogen, high 
estrogen, and contraception female groups. Consequently, White and Graham 
analysed all data based on high or low estrogen levels only. No significant SCR 
variations were seen between the four groups in habituation, acquisition and 
early/late extinction learning. On day two, fear recovery was significantly higher in 
contraception users than in high-estrogen females. Interestingly, unlike previous 
research that has found naturally cycling low estrogen females depict significantly 
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poor extinction recall compared to high estrogen females (Graham &Milad, 2013; 
Milad et al., 2010), no significant difference in fear recovery was found between 
males, females with low estrogen or females with high estrogen. The authors 
concluded that chronically low estrogen levels hinder fear extinction recall. These 
findings correspond with those of Graham and Milad, who found diminished fear 
extinction recall in females on contraception. Even though White and Graham 
controlled for the influences of sex hormones, the failure to specifically target mid-
luteal females as progesterone peaked may have added additional insight into the 
effects of divergence of progesterone across the menstrual phase. Nevertheless, the 
non-significant differences in progesterone levels foreshadowed the nonsignificant 
finding of progesterone as a predictor of fear extinction recall.   
The Effect of Progesterone on Fear Acquisition, Extinction Learning and 
Extinction Recall 
 The literature reviewed above demonstrates strong support for estrogen as an 
important mediator in fear extinction recall in females. Interestingly, while 
researchers have emphasised the importance of menstrual phase, progesterone 
(known for its role in memory consolidation; Felmingham, Fong, & Bryant, 2012) 
has, for the most part been, neglected. To our knowledge, only one human study has 
directly considered peak progesterone in mid-luteal females in a two-day fear 
acquisition and extinction task using a within-subjects design. Pineles et al. (2016) 
examined trauma-exposed females with and without posttraumatic stress disorder 
(PTSD) in both the mid-luteal (high estrogen, high progesterone) and early follicular 
(low estrogen, low progesterone) phase. Due to known effects of poor progesterone 
synthesis in females with PTSD (Rasmusson et al., 2006), Pineles et al. predicted that 
extinction recall would be comparable in PTSD females over both the early follicular 
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and mid-luteal phases. Blood samples confirmed hormone levels and menstrual 
phase. Participants completed the two-day fear acquisition and extinction task twice: 
once in the early follicular phase and again in the mid-luteal phase. Trauma exposed 
females were found to have poorer extinction recall in the early follicular phase 
compared to the mid-luteal phase, which replicates findings by Milad and Graham 
(2013). However, females with PTSD showed the opposite effect, with poorer 
extinction recall in the mid-luteal phase compared to the early follicular. Females 
with PTSD may experience variable neurological effects of sex hormones compared 
to healthy females (not reviewed in this thesis), which may explain the unexpected 
impaired fear extinction when estrogen and progesterone were high. However, 
improved extinction recall demonstrated by the trauma exposed females in the mid-
luteal phase suggests a possible role for progesterone when combined with high 
estrogen in fear extinction recall.  
 Pineles et al. (2016) study was limited by using a within-subjects design; 
women completed the fear acquisition and extinction task at two stages of their 
menstrual phase. Whilst a within-subjects design has the advantage of reducing 
individual differences, completing the conditioning task twice practice effects may 
have influenced results. Furthermore, the lack of a healthy control group prevents 
comparison between clinical and healthy populations. Since this is the only human 
study that has specifically examined mid-luteal females in relation to fear extinction, 
further research is required.  
 In summary, recent research suggests sex hormones (specifically estrogen) 
have a significant role in fear extinction and recall (Graham & Milad, 2011). While 
results appear consistent with no significant differences in fear acquisition between 
males and females in a single session, the impact of sex hormones becomes evident 
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when assessing the recall of fear extinction using a two-day paradigm (Milad et al., 
2010). Understanding the impact that menstrual cycle and levels of estrogen and 
progesterone have on fear conditioning, extinction learning and recall in healthy 
humans may offer a deeper understanding into the sex differences that have been 
observed in the prevalence of anxiety disorders (Lonsdorf et al., 2010).  
Therefore, the aims of the current study are, firstly, to replicate previous 
findings that females with low estrogen have poor fear extinction recall in a two-day 
fear acquisition and extinction paradigm, and, secondly, to investigate the 
independent effects of estrogen and progesterone on fear extinction recall in healthy 
females and males. The first hypothesis is that healthy females in the early follicular 
(low estrogen) phase will demonstrate significantly poorer fear extinction recall, 
indexed by greater SCR to a conditioned stimulus on day two of the experiment, 
compared to healthy males and healthy females in the mid-luteal phase. The second 
hypothesis, analysing the independent effects of estrogen and progesterone, predicts 
that a negative relationship between estrogen and SCR amplitude on day 2 (reflecting 
impaired extinction recall with lower estrogen) will be present but there is no specific 
directional relationship relating to progesterone given the dearth of current literature. 
Method 
Participants 
 According to a power analysis a sample size of 60 participants was required. 
Participants were recruited from the first-year psychology cohort at the University of 
Tasmania (UTAS), who were awarded 1.5 hours of course credit, and other students 
across the campus who responded to advertisements were reimbursed $20 for their 
time. The current study was built on a database previously collected at UTAS (To, 
2015).  The existing database comprised 12 males and 15 females in the early 
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follicular phase. Due to difficulty in recruiting naturally cycling females, seven of the 
female participants were on oral contraception and were tested during the sugar-pill 
week (days one to seven of the menstrual cycle). According to Pluchino et al. (2009), 
estrogen levels during menstruation of females using oral contraception are similar to 
naturally-cycling females, justifying their inclusion in this study. The current study 
extended the database by recruiting an additional six males, one female in the early 
follicular phase and 17 females in the mid-luteal phase. Data from two males, one 
mid-luteal female, and three early follicular females were excluded, two for technical 
reasons, three for abnormal hormonal levels and one voluntary withdrawal. 
Following the exclusions, a total of 45 participants: 16 males with mean age of 25.44 
years (SD = 5.84) and 29 females with mean age of 24.03 years (SD = 6.80) 
completed the study. The female participants formed two groups: early follicular 
comprised 13 individuals (7 naturally-cycling, 6 on oral contraception) and a mid-
luteal (naturally-cycling) group comprised 16 individuals. The current study 
excluded any females over the age of 45 years to control for effects on hormone 
levels of menopause, irregular menstrual cycles, and any form of hormonal 
contraception (oral, nuvaring, etonogestrel implant, hormone covered intrauterine 
devices and depot medroxyprogesterone acetate injections) and any other hormonal 
medication were excluded . Individuals with cardiovascular, neurological and 
psychiatric disorders, and anyone on steroids were also excluded. Participants were 
briefly interviewed about medication usage and medical history prior to commencing 
the experiment. Participants disclosing any exclusion criteria during the interview 
were not included in the study.  
Materials and Measures 
17 
 
 
 
 Ethics approval (Appendix A1) was obtained from the Social Sciences 
Human Research Ethics Committee at UTAS. An information sheet (Appendix A2) 
was sent to each participant prior to the experiment.  
 Medical checklist. A medical and medication use checklist was used to 
record current medication use, prior and current medical history of neurological, 
psychological and cardiovascular disorders (Appendix B1). Clinical and 
demographic information was also recorded on the checklist.  
 The Depression Anxiety Stress Scale (DASS 21). The DASS 21 
(Cronbach’s alphas of .94 for depression, .87 for anxiety and .91 for stress) was 
completed to gain insight into participants’ anxiety, stress and depressive state over 
the last week (Appendix B2). Participants responded to statements such as, “I felt 
that I had nothing to look forward to” on a four point Likert scale (Lovibond & 
Lovibond, 1995). Scores were multiplied by two to gain a score out of 42.  
 The Difficulty Emotion Regulation Scale (DERS). The DERS (with a 
Cronbach’s alpha of 0.93) was completed to assess the participants’ emotional 
regulation and emotional awareness at the start of the experiment. Participants rated 
their responses to statements for example, “I experience my feelings as 
overwhelming and out of control” on a 5 point Likert scale (AppendixB3; Gratz & 
Roemer, 2004).  
 The Catastrophic Cognitions Questionnaire-Modified (CCQ-M). The 
CCQ-M (Cronbach’s alpha of 0.88) was administered to establish an individuals’ 
perception of how dangerous they find mental and bodily sensations. Responses were 
made on a 5 point Likert scale to phrases such as “unable to control thinking” 
(Appendix B4; Khawaja, Oei, & Baglioni, 1994). 
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 The Beliefs about Emotions Scale (BAES). The BAES (Cronbach’s alpha 
of 0.91) was used to ascertain attitudes towards experiencing and revealing negative 
emotions to others for example, “It would be a sign of weakness to show my 
emotions in public”. Responses were made using a 6 point Likert scale (Appendix 
B5; Rimes & Chalder, 2010).   
 Saliva samples. Saliva samples were collected using the passive drool 
method (Gallagher, Leitch, Massey, McAllister-Williams, & Young, 2006) in saliva 
collection tubes, and assayed using standardised Salimetrics salivary Elisa and 
progesterone assay kits at a pathology laboratory at Macquarie University to assess 
estradiol (E2, the dominant form of free bioavailable estrogen) and progesterone 
levels, and to confirm menstrual phase. Thawed salivary samples were centrifuged at 
1500 x g for 15 min.  
Fear acquisition and extinction. A two-day fear acquisition and extinction 
paradigm (adapted from Milad et al., 2006) was used for the experiment. Skin 
conductance electrodes, AD Instruments, Inquisit 3.0.6.0 program and lab chart 
software were used to conduct the fear conditioning and extinction task and record 
output data. A Powerlab 16/35 Stimulus Isolator was used to deliver the electrical 
stimulus.  
Procedure 
 Female participants contacted the researcher either by telephone or email on 
the first day of menstruation. Females allocated to the early follicular group were 
booked into the Psychology Research Centre to complete the experiment between 
days two and seven of their menstrual cycle. Females allocated to the mid-luteal 
group completed the experiment on days 19 and 20 or 20 and 21of their cycle. On 
day one, the procedure was explained and written informed consent obtained 
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(Appendix A3). A checklist confirming medical history, hormonal contraception and 
medication use was completed. Participants completed the DASS 21, DERS, CCQ-
M, and BAES questionnaires. A saliva sample was collected, labelled and frozen at-
20°C. SCR electrodes were placed on the first and third finger of the non-dominant 
hand, and the electrical stimulus electrode placed between the thumb and index 
finger on the dominant hand. Participants chose the strength of the electrical impulse 
starting at 2mA and increasing by 0.5mA, until the stimulus was reported to be 
significantly uncomfortable but not painful. The system was calibrated to zero 
(before establishing baseline SCR for each participant) prior to commencing the fear 
acquisition and extinction paradigm. Day one of the fear acquisition and extinction 
paradigm was then completed. The visual stimuli consisted of orange and green 
circles. The CS
+
 function was randomly assigned in order to counterbalance the 
stimuli among participants. 
 The green and orange circles, 7 centimetres in diameter, were presented on a 
screen for twelve seconds. The inter-trial intervals ranged between 12 and 21 seconds 
with a mean of 16 seconds. Prior to commencing the experiment, participants were 
asked to keep as still as possible, in order to reduce SCR artefact. As shown in Figure 
5, day one comprised of four phases: habituation, acquisition, early extinction, and 
late extinction. For the habituation phase, participants were advised that they would 
not receive an electrical stimulus. The habituation phase presented eight trials (4 
green circles, 4 orange circles) in a randomised order. This was followed by the 
acquisition phase. Prior to the commencement of the acquisition phase participants 
were informed they may or may not receive an electrical stimulus and were reminded 
to keep as still as possible. The acquisition phase presented a total of 16 trials (8 
green circles, 8 orange circles). Five out of the eight CS
+ 
trials were paired with a 50-
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millisecond electrical stimulus (62.5% reinforcement). Acquisition was followed by 
the early extinction phase, which presented 10 trials (5 green and 5 orange circles). 
Finally, the late extinction phase presented 10 trials (5 green and 5 orange circles).  
 
 
 
 
 
Figure 5: Phases and trials of the fear acquisition and extinction paradigm on day 
one. 
 
 
 
 
 
Figure 6: Phases and trials of fear extinction recall on day two.  
 Participants returned to the laboratory the following day (day two), for the 
assessment of extinction recall. The SCR electrodes and electrical stimulus electrode 
were attached and the system calibrated as per day one. Participants were reminded 
to keep as still as possible during the task. No instructions regarding the presence or 
absence of the electrical stimulus were given.  As illustrated in Figure 6, the early 
extinction recall and late extinction recall phases replicated the extinction phases on 
day one, with 10 trials  (5 green and 5 orange circles) in early extinction recall and 
10 trials  (5 green and 5 orange circles) in late extinction recall. In addition, for 
contingency awareness of the CS
+
 and CS
-
, as a manipulation check, participants 
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were asked if they knew which colour was associated with the electrical stimulus. 
Participants were then debriefed and thanked for their participation.  
Design and Analysis 
Consistent with previous research, a repeated measure between-factors design 
was used, with repeated measures mixed-model analyses of variance (ANOVA) to 
analyse data (Glover et al., 2012; Inslicht et al., 2013; Wegerer et al., 2014). The 
average SCR of the 2 second pre-stimulus mean was calculated to gain a baseline 
skin conductance level for each participant. To measure the change in SCR 
amplitude the two-second pre-stimulus mean was subtracted from the highest SCR 
value recorded during the 12-second CS presentation for each trial in each phase. In 
line with previous research, each SCR value was square root transformed to reduce 
heteroscedasticity. For negative values, the absolute number was found, square root 
transformed, and the negative sign replaced (Inslicht et al., 2013; Milad et al., 2010). 
Data collected by To (2015) and data from the current study were collated and 
analysed using SPSS version 23.  
 To test hypothesis one, a series of separate 3 (Group: males, early follicular 
females, mid-luteal females) x 2 (Condition: CS
+
, CS
-
) x 4 or 5 (Trial) repeated 
measures ANOVAs were conducted, with SCR amplitude as the dependent variable. 
Trial one in the acquisition phase was not included in the analysis, as an increase in 
SCR in the first trial is probably a consequence of given instructions (may or may not 
receive an electrical stimulus) rather than conditioning (Inslicht et al. 2013) as no 
electrical stimulus pairings had been made. Trials after trial five in acquisition were 
not analysed as SCR tends to decline towards the end of the acquisition phase (Milad 
et al., 2010). To analyse extinction recall, the percentage value of the fear retention 
index was calculated by dividing the combined average SCR for early extinction 
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recall and late extinction recall trials by the maximal SCR for a CS
+
 during fear 
acquisition and multiplying by 100. This was followed by a one-way ANOVA to test 
differences across groups (Graham & Milad, 2011; Milad et al., 2010). For one-way 
ANOVA’s Levene’s test of homogeneity of variance was checked for violation 
(Allen & Bennett. 2012). For repeated measure ANOVAs, Greenhouse-Geisser 
correction was applied when Mauchly’s test of sphericity was violated (Field, 2009). 
For multiple comparisons, Sidak corrections were used with the alpha level set at .05 
for statistical significance (Allen & Bennett. 2012). To test hypothesis two, a 
hierarchical regression was conducted with fear recovery index as the outcome 
variable and estradiol and progesterone as the predictor variables (White & Graham, 
2016). Cooks distance was used to determine possible outliers and the VIF and 
Tolerance were checked for multicollinearity (Allen & Bennett, 2012).  
Results 
Demographic and Clinical Data.   
 Univariate ANOVAs were conducted on demographic and clinical data, with 
means and standard deviations presented in Table 1. There were no significant 
differences between the groups in scores on the DASS (Depression, Anxiety, and 
Stress), CCQ-M, DERS, BMI, hours awake, or stimulus intensity. Salivary levels of 
estradiol, F(2, 42) = 3.54, p = .038, ηp
2 
= .14, and progesterone, F(2, 42) = 14.76, p 
<.001, ηp
2 
= .41, were significantly different between the groups (group means are 
included in Table 1 and see Figure 7). Assays with a coefficient of variation (CV%; 
repeated measurement of same sample to determine deviation and consistency) 
<10% were considered for analysis (Chesher, 2008; Salimetrics Inc; Appendix C).  
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Table 1.  
Demographic and Clinical Data for Early Follicular Females, Mid-luteal Females 
and Males 
____________________________________________________________________                                 
                               Early Follicular       Mid-luteal         Males            F        p      ηp
2 
   Females       Females 
                       _________________________________________ 
M   SD                   M   SD              M   SD   
____________________________________________________________________ 
DASS Depression     2.92 (2.14)        4.38 (4.46)       3.81 (4.89)       0.45   .641   .02 
DASS Anxiety          5.00 (4.81)        4.38 (4.46)       3.88 (6.43)       0.16   .849   .01 
DASS Stress             6.62 (3.80)        8.69 (5.87)       6.13 (6.76)       0.89   .418   .04 
CCQ-M                     58.38 (13.79)    60.56 (13.50)   50.19 (14.69)   2.41   .103   .10 
DERS                        90.69 (20.67)    75.00 (16.36)   82.34 (16.64)   2.70   .073   .12 
Age                           25.00 (7.48)       23.25 (6.32)    25.44 (5.84)      0.50  .611   .02 
BMI                          21.52 (3.18)       23.08 (4.40)    23.25 (3.75)      0.85  .436   .04 
Hours awake             6.65 (2.19)         5.03 (3.11)       5.63 (2.99)       1.19  .314   .05 
Stimulus (mA)         1.8 (0.5)                2.1 (0.5)            2.1 (0.3)        1.76    .185    .07 
Progesterone            38.46 (49.50)       161.11 (111.55)
* 
34.61 (28.79) 
Estradiol                   2.07 (0.63)            2.57 (0.65)        1.95 (0.77)
* 
CS
+ 
ID (N)               8                           10                       13 
Note. CS+ ID = CS+ correct identification.  * p < .05 
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 Figure 7.  Mean progesterone and estradiol salivary levels in the early follicular, 
male and mid-luteal groups. Error bars are standard error. * p <.050.              
 For progesterone the assay sensitivity was 5.0 pg/ml. The intra-assay 
variability was 5.4% and inter-assay variability was 5.9%. For estradiol levels the 
assay sensitivity was 0.1 pg/ml. The intra-assay variability was 5.9% and the inter-
assay variability was 6.4%. Since a one-way ANOVA found no significant 
differences in baseline SCR across groups, F(2, 42) = 0.08, p = .924, ηp
2
 = .004, 
group differences found between early follicular females (EF), mid-luteal females 
(ML) and males are not attributed to the findings presented below.  
Skin Conductance Response 
 Data were screened for missing values and outliers. No data points were 
missing. Two data points (one in the ML group and one in the male group) were 
identified as outliers. These two values were corrected to three standard deviations 
above the mean before analyses were conducted (Tabachnick & Fidell, 2001). Mean 
SCR for each phase on day one is presented in Figure 8.  
 Habituation. A 3 x 2 x 4 (Group [male, EF, ML] x Condition [CS
+
, CS
-
] x 
Trial [1, 2, 3, 4]) repeated measures ANOVA revealed a significant effect of trial, 
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F(3, 126) = 9.90, p <.001, ηp
2
= .19. Sidak-corrected pairwise comparisons found 
SCR in trial 1 (M = 0.76) was significantly higher than trial 3 (M = 0.47), p <.001, 
95% CI [0.12, 0.47] and trial 4 (M = 0.53), p = .011, 95% CI [0.04, 0.42].   
In addition, SCR in trial 2 (M = 0.72) was significantly higher than trial 3, p = .004, 
95% CI [0.06, 0.44] and trial 4, p = .045, 95% CI [0.01, 0.37]. No significant effect 
of group, F(2, 42) = 0.30, p = .746, ηp
2
 = .01, or condition, F(1, 42) = 0.10, p =.756, 
ηp
2
 = .002, was found. There was no significant interaction for Condition x Group 
F(2, 42) = 1.66, p = .200, ηp
2
 = .07, Trial x Group, F(6, 126) = .81, p = .567, ηp
2
 = 
.04, Condition x Trial, F(3, 126) = 0.31, p = .815, ηp
2 
=.01, or for Group x Condition 
x Trial, F(6, 126) = 0.72, p = .637, ηp
2
 = .03.  
 
 
 
Figure 8.  Mean skin conductance, collapsed across groups, in habituation, 
acquisition, early extinction and late extinction. Error bars are standard error. 
 Acquisition. A 3 x 2 x 4 (Group [male, EF, ML] x Condition [CS
+
, CS
-
] x 
Trial [2, 3, 4, 5]) repeated measures ANOVA found a significant effect of condition, 
F(1, 42) = 9.15, p = .004, ηp
2
 = .18. A Sidak-corrected pairwise comparison found 
that SCR in the CS
+ 
condition was significantly higher (M = 0.81) than the CS
-
 
condition (M = 0.63), p = .004, 95% CI [0.06, 0.31], implying SCR increased during 
fear conditioning. There were no significant effects of group, F(2, 42) = 0.002, p = 
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.998, ηp
2
 < .00, or trial, F(3, 126) = 0.87, p = .458, ηp
2
 = .02. There was no significant 
interaction between Condition x Group, F(2, 42) = 1.23, p = .303, ηp
2
 = .05, Trial x 
Group, F(6, 126) = 0.47, p = .830, ηp
2
 = .02, Condition x Trial, F(3, 126) = 1.15, p = 
.332, ηp
2
 = .03, or Group x Condition x Trial, F(6, 126) = 0.97, p = .455, ηp
2 
= .04.  
 Early extinction. A 3 x 2 x 4 (Group [male, EF, ML] x Condition [CS
+
, CS
-
] 
x Trial [1, 2, 3, 4, 5]) repeated measures ANOVA established a significant effect of 
trial, F(3, 129) = 5.51, p =.001, ηp
2
 = .12. Sidak-corrected pairwise comparisons 
found SCR amplitude for trial 1 (M = 0.78) was significantly higher than trial 3 (M = 
0.50), p = .033, 95% CI [0.14, 0.55], and trial 5 (M = 0.47, p = .026, 95% CI [0.02, 
0.59], reflecting reduced SCR amplitude across extinction trials. There was no 
significant effect of group, F(2, 42) = 0.33, p = .720, ηp
2
 = .02, or condition, F(1, 42) 
= 0.45, p = .833, ηp
2 
< .00. There was no significant interaction for Condition x 
Group, F(2, 42) = 1.65, p = .204, ηp
2
 = .07, Trial x Group, F(6, 129) = 0.35, p = .915, 
ηp
2
 = .02, Condition x Trial, F(4, 168) = 1.51, p = .201, ηp
2 
= .04, or Group x 
Condition x Trial, F(8, 168) = 0.27, p = .974, ηp
2 
= .01.  
 Late extinction. A 3 x 2 x 4 (Group [male, EF, ML] x Condition [CS
+
, CS
-
] 
x Trial [1, 2, 3, 4, 5]) repeated measures ANOVA revealed a significant main effect 
for trial, F(3, 126) = 3.68, p = .014, ηp
2
 = .08. Sidak-corrected pairwise comparisons 
found the SCR amplitude in trial 1 (M = 0.71) was significantly higher than trial 2 
(M = 0.50), p = .048, 95% CI [0.001, 0.44], and trial 5 (M = 0.44), p = .009, 95% CI 
[0.05, 0.50], reflecting a general reduction in SCR amplitude across late extinction 
trials. There were no further significant main effects of group, F(2, 42) = 0.71, p = 
.498, ηp
2
 = .03, or condition, F(1, 42) = 0.01, p = .914, ηp
2 
< .00. There was no 
significant interaction for Condition x Group, F(2, 42) = 0.12, p = .892, ηp
2 
= .01, 
Trial x Group, F(6, 126) = 1.30, p = .261, ηp
2 
= .06, Condition x Trial, F(4, 168) = 
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1.12, p = .356, ηp
2
 = .03, or Group x Condition x Trial, F(8, 168) = 1.18, p = .314, ηp
2
 
= .05. 
Fear Extinction Recall 
 Fear retention index. As described above a fear retention index was 
calculated. A univariate ANOVA was conducted for fear retention index percentage, 
finding a significant effect for group, F(2, 42) = 4.27, p = .021, ηp
2
 = .17. As shown 
in Figure 9, Sidak-corrected pairwise comparisons revealed that the EF group had 
significantly higher fear retention (M = 57.28%) than the ML group (M = 31.73%), p 
= .022, 95% CI [2.99, 48.12]. This difference in means suggest that early follicular 
females have inhibited fear extinction recall. The male group (M = 49.09%) did not 
significantly differ from either the ML group, p = .142, 95% CI [-4.01, 38.73], or the 
EF group, p = .752, 95% CI [-30.76, 14.37]. 
               
        
Figure 9.  Fear retention index percentage in fear extinction recall for early follicular 
females, males and mid-luteal females. Error bars are standard error. * p < .05 
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 A hierarchical regression was employed to assess estradiol and progesterone 
as predictors of fear recovery index. As seen in Table 2, regression results for both 
estradiol and progesterone were non-significant. 
Table 2 
Hierarchical Multiple Regression Predicting Fear Recovery Index 
                 Predictor               B [95%CI]                      t         p             R
2
        ΔR2 
______________________________________________________________________________________________________ 
Step one                                                                                                     0.001    0.001    
 Estradiol               0.89 [-10.07, 11.85]          0.16            .871          
Step two                                                                                                     0.03      0.03 
Estradiol         4.33 [-8.01, 16.67]            0.71            .483 
Progesterone         -0.06 [-0.15, 0.04]           -1.20           .245                
____________________________________________________________________
Note. CI = Confidence interval. N = 45 
 
Discussion 
 The current study aimed to replicate the finding that females in the early 
follicular phase of the menstrual cycle had diminished fear extinction recall (memory 
of extinction training from day one), demonstrated by greater SCR amplitude and a 
high fear retention index compared to males and females in the mid-luteal phase. The 
results revealed no significant differences in fear extinction recall between the early 
follicular females and males however, early follicular females had significantly 
poorer fear extinction recall compared to mid-luteal females suggesting that 
menstrual phase impacts fear extinction recall in females, thereby replicating 
previous research. Further, the study aimed to investigate the independent effects of 
estrogen and progesterone in fear extinction recall across early follicular females, 
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mid-luteal females and males. The prediction of a negative relationship between 
estrogen and SCR amplitude on day two was unfound. Unexpectedly, the analysis of 
independent effects of the two sex hormones did not yield estradiol or progesterone 
as significant predictors of fear retention.  
Fear Acquisition  
 During fear acquisition all three groups demonstrated robust fear conditioning 
through a significant escalation in SCR amplitude across the acquisition phase.  . 
This is consistent with previous studies that used SCR data to determine adequate 
fear acquisition in males, low estrogen, and high estrogen females in healthy and 
clinical groups (Glover et al., 2012; Milad et al, 2010). Reflecting on reviewed 
literature by Graham and Milad (2013), Wegerer et al. (2014), and White and 
Graham (2016) who found consistently higher SCR in the CS 
+ 
condition compared 
to CS
-
 condition, the current study also found a significant main effect of condition. 
This proposes that participants became aware of the CS 
+ 
and electric stimulus 
pairing, demonstrating contingency awareness (correct identification of the CS 
+ 
stimulus). This was further evidenced by a continuation of elevated SCR in CS 
+ 
trials despite the study only using a 62.5% reinforcement rate. In other words, higher 
SCR remained persistent even though only five of the eight CS 
+ 
presentations were 
paired with the electrical stimulus. According to Warren et al. (2014), the elevated 
SCR in CS
+
 presentations demonstrates successful association with danger compared 
to lower SCR in CS
-
 presentations  which implies an associated with safety signals. 
Furthermore, data analysis of acquisition SCR did not find a significant effect of 
group. This parallel’s the lack of group effects in studies conducted by Glover et al. 
(2012), Graham and Milad (2013), and White and Graham (2016). Consequently, 
learned fear occurred irrespective of sex or menstrual phase and therefore later 
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significant effects cannot be attributed to differences in fear learning. Lastly, Kelly 
and Forsyth (2007) argue that increased SCR in fear acquisition demonstrates the 
paradigms ability to induce learned fear. As an increase in SCR was observed during 
the acquisition phase this lends support for the current study’s adapted fear 
acquisition and extinction paradigm to effectively induce a conditioned fear 
response. 
Fear Extinction Learning 
 Fear extinction learning occurred over two phases (early extinction and late 
extinction). According to Stockhorst & Antov (2016) extinction learning (defined as 
significantly lower SCR from acquisition) promotes a new form of inhibitory 
learning concerning the association between CS
+
 and CS
-
. Participants learn that the 
aversive stimulus will no longer be administered which consequently reduces the 
CR. The current study found no main effect of condition, where SCR between CS
+
 
and CS
-
 conditions were no longer significant suggesting the conditioning effects 
seen, in terms of elevated SCR, during acquisition had dissipated. This coincides 
with results found by Milad et al. (2010), Graham and Milad (2013), and Graham 
and White (2016) were the effects observed in conditioning were no longer present. 
In addition, the reduction in SCR in the CS
+
 and CS
-
 condition reflected inhibitory 
learning (Glover et al., 2013).  
 The repeated measures ANOVA conducted in early extinction found a 
significant effect of trial demonstrating a significant decrease in SCR amplitude in 
the later trials (trial 3 and 5) compared to the early trials (trial 1). This was followed 
by a further reduction in SCR amplitude in the late extinction trials (trials 1 and 2) 
with plateau in the later trials (no further significant reductions in SCR after trial 2) 
suggesting fear extinction learning was successful. The pattern of results obtained for 
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the extinction learning trials correspond with those of Graham and Milad (2013), 
Milad et al. (2010), Wegerer et al. (2014), and White and Graham (2016). These 
studies concluded that significant decreases in SCR across trials demonstrated robust 
extinction learning. Furthermore, the current study found no main effect of group. 
Consistent with previous findings by Milad et al. (2010), Wegerer et al. (2014), and 
White and Graham (2016) the SCR amplitude measured in both early and late 
extinction in the current study was comparable between the groups. Similar to 
acquisition, fear extinction learning was comparable across groups with no evidence 
of differences attributed to sex (males and females) or menstrual phase. 
 According to Kelly and Forsyth (2007) the US in laboratory based fear 
acquisition and extinction paradigms is not a true reflection of external (‘real world’) 
fear-inducing stimuli. In addition, they argue that the absence of clinical samples 
(who are known to demonstrate resistant extinction learning, Duits et al., 2015) 
affords rapid reduction in SCR in experimental sessions. However, in opposition, 
Miskovic and Keil (2012) argue that while dysfunctional extinction learning 
(continuous CR to CS
+ 
and CS
- 
stimuli without the aversive stimulus) can be present, 
it is the outcomes that emerge on day two which offers the greatest insight into 
identifying maladaptive fear extinction recall. As poor memory of extinction 
learning, despite evidence of adequate in-session extinction, occurs in healthy 
samples it informs potential reasons behind persistent fear responses observed in 
clinical samples.    
Fear Extinction Recall 
 The first hypothesis predicted that early follicular females would demonstrate 
poor fear extinction recall compared to males and mid-luteal females. Most research 
has compared females in the early and late follicular phases (low and high estrogen, 
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respectively) and found deficits in extinction recall in early follicular females. This 
has been attributed to low estradiol levels, but few studies have compared the early 
follicular phase with the mid-luteal phase, which is characterised by peak 
progesterone levels and relatively high estradiol levels. The results reported here for 
the fear extinction recall phase revealed a significant effect of group. Fear extinction 
recall was significantly lower in early follicular females (demonstrated by high fear 
retention index) who had higher SCR amplitude during the early and late fear 
extinction recall trials compared to the mid-luteal females. Furthermore, comparable 
SCR amplitude between early follicular and mid-luteal females during extinction 
learning substantiates the view that discrepancies between these groups are a 
consequence of poor extinction memory consolidation. This partially supports our 
initial hypothesis. Based on self- reported menstrual phase, this finding suggests that 
females in episodes of low estrogen tend to experience reduced extinction recall 
when the original CS
+
 is presented after a 24 hour latency. This finding replicates the 
increased fear retention found by previous researchers in early follicular females 
when tested on day two of a fear acquisition and extinction recall paradigm (Graham 
& Milad; Milad et al., 2010; White & Graham; 2016). However, these findings 
contradict those of  Lonsdorf et al. (2014) who found no difference in SCR data 
between the follicular and luteal females on day two of their study and Pineles et al. 
(2016) who discovered mid-luteal females with PTSD demonstrated poor extinction 
recall in mid-luteal females. The differences found in fear extinction recall in the 
mid-luteal females in the current study and those of Pineles et al. is likely  due to 
testing  healthy versus clinical populations and variations in hormonal synthesis 
known to occur in individuals with PTSD (Maeng & Milad, 2015; VanElzakker et 
al., 2014). In contrast to the hypothesis, early follicular females did not differ 
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significantly from males in fear extinction recall but they displayed a pattern of 
higher SCR in the early and late extinction recall phase. This trend (increased fear 
retention in early follicular females) is consistent with previous research by other 
laboratories who have reported poor fear extinction recall in early follicular females 
compared to males, nevertheless as this is not a significant finding it should be 
interpreted with caution. More importantly to note, the overall effect was driven by 
the differences in fear recovery between the two female groups. 
Salivary Measures of Estrogen and Progesterone 
 Previous research has attributed differences in extinction recall across 
menstrual phases to low levels of estradiol, and convincing evidence of this has been 
found in animal studies and in pharmacological-challenge studies in both rats and 
humans (Graham & Milad, 2011; Graham & Milad, 2013; Milad et al., 2009). In the 
current study, salivary measures revealed that progesterone clearly discriminated 
between the menstrual groups. Congruent with expectations, the mid-luteal females 
displayed significantly greater progesterone levels than the early follicular females 
and males.  As mid-luteal females demonstrated superior fear extinction recall, it is 
unrealistic to exclude progesterone as a possible mediator in fear extinction recall 
which parallels findings in animal studies of female rats over the menstrual phase 
(Milad, Igoe, LeBron-Milad & Novales, 2009). Unexpectedly, in the present study, 
salivary estradiol did not significantly differ between early follicular and mid-luteal 
females, although means for early follicular females were in the expected direction 
(see Figure 7; Lu, Bentley, Gann, Hodges, & Chatterton, 1999). It is possible that 
this null finding may be due to difficulties associated with the salivary assay for 
estradiol, as it rapidly deteriorates after thawing (Toone et al., 2013) which in turn 
can compromise data quality. Thus, this null finding in estradiol could be due to 
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artefact and requires further exploration before conclusions can be drawn regarding 
the role of estrogen as an important modulator in achieving adequate fear extinction 
recall.  
 The study further aimed to explore how progesterone may impact fear 
extinction recall. As there is no known research that has directly investigated peak 
progesterone (in mid-luteal females) in a fear acquisition and extinction recall 
paradigm, no directional hypothesis was made. A hierarchical regression was 
conducted in an attempt to evaluate the independent effects of estrogen and 
progesterone. In the regression analysis detailed in Table 2, neither sex hormone was 
found to be a significant predictor of fear extinction recall. This finding is surprising, 
especially for estrogen, as there is a wealth of evidence implicating estrogen as a 
dominant factor in achieving a reduction in fear retention when testing the adequacy 
of fear extinction recall in females (Glover et al., 2012; Graham & Milad, 2013; 
Milad et al., 2010; Stockhorst & Antov, 2016; White & Graham, 2016). However, 
this null result is likely explained by the difficulties in assaying estradiol from saliva 
(as described above).  
The high level of salivary progesterone appears to be valid, and the regression 
analysis suggests that there was no significant relationship between progesterone and 
fear extinction recall.  This supports a recent study which found that progesterone 
was not a significant predictor of fear extinction recall (White & Graham, 2016).  
Our current findings diverge from Graham and White’s study in that they found 
estrogen to be a significant predictor of fear extinction recall. Possible explanations 
for the observed differences include that White and Graham used blood samples to 
test hormonal levels which varies from levels found in saliva.  In addition the 
inconsistency found in the current study may have been a result of potentially 
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compromised salivary estradiol analysis. In addition, the lack of effects due to 
progesterone is interesting, considering that progesterone has been found to facilitate 
extinction recall in animal studies (not included in this study; Milad et al., 2009). 
Furthermore, combining several factors: emotional properties given to a fearful 
experience (CS
+ 
stimuli), high levels of progesterone in the mid-luteal females, a 
significant main effect of progesterone in fear extinction recall and well-established 
knowledge that progesterone enhances emotional memory consolidation, one would 
expect to have found some portion of variance explained (Ertman, Andreano, & 
Cahill, 2011; Felmingham et al., 2012; LeBron-Milad & Milad, 2012; Maeng & 
Milad, 2015; Zorawski et al., 2005). Whilst the null effect of progesterone may be a 
real finding, it does require replication as it may also have been impacted by a lack of 
statistical power. The required number of participants in the a priori power analysis 
was not achieved hence this may have led to undetermined effect size and an inflated 
risk of type II error (Austin & Steyerberg, 2015; Nakagawa, 2004). 
Limitations and Future Research 
There are limitations within this study worth noting. Firstly, the study was 
underpowered due to clinical and technical reasons and, most importantly, the 
difficulty in recruiting females who do not use any form of contraception. Secondly, 
the limited sample size compromised the detection of adequate effect sizes. Future 
research should recruit larger samples in order to replicate and extend current and 
previous research findings.  
 Another potential limitation relates the collection of salivary samples per 
participant. The estradiol levels in the mid-luteal females were unexpectedly lower 
than anticipated. There was a delay in the assay of estradiol as the laboratory’s 
estradiol testing kit supply was depleted. Consequently, estradiol levels were 
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measured approximately seven days after the progesterone levels. This raises the 
possibility of inaccurate estradiol measurements. Even though the laboratory 
reported a one freeze thaw cycle it is unknown how long the saliva samples remained 
unfrozen and refrigerated or left at room temperature until assay of estradiol. 
According to Toone et al. (2013) salivary estradiol levels significantly decreases as 
days pass, irrespective of refrigeration or room temperature, post thawing. An 
alternative for measuring hormonal status may include blood serum analysis 
(measuring protein bound estrogens) as it is less sensitive to deterioration (Lu et al., 
1999) and may improve the integrity of biological analyses. In addition, even though 
salivary collection is seen as advantageous in terms of its non-invasiveness and self-
collection, salivary hormone levels are known to fluctuate on a daily basis which 
may confound accurate estradiol readings (Gandara, Leresche, & Mancl, 2007). 
Consequently, future research considering the use of salivary measures could obtain 
a saliva sample on both days of the paradigm and average the two reported hormonal 
levels to improve reliability (Wegerer et al., 2014).  
 Males have estrogen and progesterone levels comparable to females in the 
early follicular phase, yet males do not develop anxiety disorders at the same rate of 
females (Kessler et al., 2005; Milad et al., 2010). This may be influenced by 
testosterone which is substantially higher in males compared to females (Ackermann 
et al., 2012). As testosterone is metabolised into estrogen to achieve homeostasis 
(predominately seen in males when estrogen is low) and a males’ capacity to rapidly 
convert testosterone to estrogen and decrease fear response (Pace-Schott et al., 
2013), this makes for interesting analyses of fear extinction recall in males. As the 
relationship between fear extinction recall and testosterone is rather understudied, 
future research in the field of sex hormones and fear extinction learning and recall 
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may include assessment of testosterone to assess its independent effects on extinction 
recall. Furthermore, as the study only focused exclusively on the effects of estrogen 
and progesterone it is important to acknowledge the role of cortisol. Cortisol is a 
hormone known to influence fear learning, fear extinction and memory (de Quervain 
et al., 2011; Hwang et al., 2013). According to Kirschbaum, Kudielka, Gaab, 
Schommer and Hellhammer (1999) cortisol levels fluctuate in females over the 
menstrual cycle and may therefore also influence the disparity in extinction recall 
found between males and females as well as females in different times of their 
menstrual cycle. Measuring cortisol in conjunction with other sex hormones can 
further investigate how the combinations of hormones impact fear acquisition, 
extinction learning and extinction recall.    
 Furthermore, with regards to females, estrogen fluctuates across the 
menstrual cycle. As studies typically only assess fear acquisition, fear extinction and 
extinction recall in either the early and late follicular phases or the early follicular 
and luteal phases, the inclusion of a mid-cycle group (where estrogen is at its highest 
and progesterone remains low) could deepen the understanding of how estrogen and 
progesterone impact fear extinction recall (Glover et al., 2013; Graham & Milad, 
2013; Lonsdorf et al., 2014; Wegerer et al., 2014).  
Implications and Conclusions 
Bearing in mind that some treatments for anxiety disorders involve fear 
extinction, it is imperative to incorporate knowledge obtained through empirical 
studies concerning the role of menstrual phase on fear extinction learning and 
extinction learning recall in females. Since drawing conclusions based on assessment 
of hormone levels is inappropriate in this study, clinical implications are derived 
from self-reported menstrual phase. Targeting exposure related treatment to coincide 
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with late follicular and luteal phases (when levels of estrogen and progesterone are 
elevated) may significantly improve treatment outcomes in female clients, such as 
reduced symptom severity, improved quality of life, and decreased rates of relapse 
(Duits et al., 2015; Graham & Milad, 2011; Graham & Milad, 2013; White & 
Graham, 2016).  
 In summary the current study replicated previous research that have found 
substantial evidence supporting diminished fear extinction recall in early follicular 
females. Confirming the initial hypothesis, testing of fear extinction recall in a two-
day fear conditioning and extinction paradigm found that early follicular females 
demonstrated impaired fear extinction recall compared to mid-luteal females. The 
regression analysis revealed no relationship between progesterone and fear extinction 
recall and unexpectedly, failed to find a relationship between estrogen and fear 
extinction recall which may have been due to reduced sensitivity of estradiol salivary 
data and under-powering of the study. Future research could usefully analyse 
estrogen and progesterone across the menstrual phase, in order to better understand 
how progesterone fits into fear extinction learning and recall. Immediately, however, 
the findings of this study substantiate the view that optimal treatment regimes for 
anxiety disorders in females requiring fear extinction should include careful 
consideration of their menstrual cycle. 
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Appendix A1 
Ethics Amendment Approval: H0012496 Sex differences in 
fear extinction: The influence of cognitive variables 
 
 
Katherine Shaw 
Mon 11/04/2016 10:51 AM 
 
To: Kim Felmingham <kim.felmingham@utas.edu.au>; 
 
Cc:Cheryl McKay <mckaycl@utas.edu.au>; 
 
 Dear Professor Felmingham 
 
Ethics Ref: H0012496 
Title: Sex differences in fear extinction: The influence of cognitive variables 
 
This email is to confirm that the following amendment was approved by the Chair of the 
Tasmania Social Sciences Human Research Ethics Committee on 8/4/2016: 
 
· Change of investigators: removal of Annie To, as she has completed her master’s  thesis. 
 
· Addition of Honours student Cheryl McKay who will collect an additional experimental group 
(a midluteal  group). 
 
· Revised Information Sheet. 
 
All committees operating under the Human Research Ethics Committee (Tasmania) Network 
are registered and required to comply with the National Statement on Ethical Conduct in 
Human Research (NHMRC 2007, updated May  2015). 
 
This email constitutes official approval. If your circumstances require a formal letter of 
amendment approval, please let us know. 
Should you have any queries please do 
not hesitate to contact me. Kind 
regards 
Katherine 
 
Katherine Shaw 
Executive Officer,  
Social Sciences 
HREC Office of 
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Research 
Services | 
Research 
Division 
University of 
Tasmania 
Private Bag 1 
Hobart TAS 7001 
T +61 3 6226 2763 
[www.utas.edu.au/research]www.utas.edu.au/research 
 
CRICOS 00586B 
 
 
 
 
 
University of Tasmania Electronic Communications Policy (December, 2014). 
This email is conﬁdential, and is for the intended recipient only. Access, disclosure, copying, 
distribution, or reliance on any of it by anyone outside the intended recipient organisation is 
prohibited and may be a criminal oﬀence. Please delete if obtained in error and email conﬁrmation 
to the sender. The views expressed in this email are not necessarily the views of the University of 
Tasmania, unless clearly intended otherwise. 
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Appendix A2 
 
 
Participant Information Sheet 
  
 
Title:  Sex differences in fear extinction  
Date: 
 
Invitation 
You are invited to participate in a research study examining the influence of hormones 
on fear extinction.  This study will be carried out in the Cognitive Neuroscience (ERP) 
Laboratory at the School of Psychology, University of Tasmania (Hobart).  This study is 
being conducted by Cheryl McKay(Honours student), supervised by Professor Kim 
Felmingham in partial fulfilment of the requirements of their honours studies in the 
School of Psychology, University of Tasmania. 
What is the purpose of this study? 
The purpose of this study is to investigate the influence of hormones on fear conditioning 
and extinction which are key processes thought to underlie the development and 
treatment of anxiety disorders.  Recent evidence reveals that cognitive variables and sex 
may influence the rates of fear conditioning and extinction, but few studies have examined 
the influence of hormones. 
Why have I been invited to participate? 
You have been invited to participate in this study as you are a healthy male or female, 
between the ages of 18 to 55, who are not currently taking any medication, and who have 
no history of psychiatric disorders. We will ask you to complete a questionnaire about these 
conditions before the experiment begins. In exchange for your participation, you will be 
learning about the processes of psychological research and you will receive $20 for the hour 
and a half of experimental research, or 90 minutes of course credit in psychology. 
What will I be asked to do? 
You will be asked to come in for two testing sessions at the University of Tasmania, the first 
will take approximately 60 minutes and the second (24 hours later) will take approximately 
30 minutes. The study will be run in the Cognitive Neuroscience Laboratory in the School of 
Psychology.  In the first session, you will be asked to sit in a quiet room and complete some 
questionnaires about your mood, beliefs and cognitive processing style. You will also be 
asked to fill in a medical history questionnaire, which will ask about the position that you 
are in your menstrual cycle and contraceptive use (if you are female). The study will also 
require taking saliva samples (collecting saliva in a small plastic tube).  The samples will be 
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examined by laboratory technicians to measure your current levels of estrogen, 
progesterone, noradrenaline and cortisol. You will then complete a behavioural task which 
examines how your body arousal (sweat gland activity) reacts to a mild electrical stimulus 
that will be administered to your fingertips. You will first be asked to select a level of mild 
electrical stimulus that feels uncomfortable but not painful to you. This will be done by 
attaching a finger stimulator to your index finger and delivering the lowest level of electrical 
stimulus, the level of which will then be increased in small increments until you report that 
it feels uncomfortable but not painful. You will then be asked to complete the behavioural 
task. In this task, you will sit in front of a computer screen and small recording disks will be 
attached to your finger tips to measure your body arousal (via skin conductance). You will 
then be asked to watch the computer screen on which you will see different coloured 
circles appear. Following the presentation of some of these coloured circles, you will 
receive an electrical stimulus which will be set at the level which you have previously 
chosen. You will also be asked to provide ratings on how much you are expecting to receive 
the electrical stimulus in the task.  The behavioural task will last approximately 15 minutes.  
In the second session, you will be asked to provide a second saliva sample and then 
complete one part of the behavioural task again.  This will involve having small recording 
disks and the finger stimulator to your fingers, and observing the coloured circles.  In this 
second testing session, you may or may not receive electric shocks. 
What will happen to my sample after it has been tested? 
Your saliva sample will only be used for the purpose of this research study.  The saliva 
samples you provide during the study will be destroyed at the completion of the study.  
Your saliva samples will not be used for genetic testing or disease markers. 
Will I be able to get my sample back if I want? 
No, your saliva sample will be destroyed following laboratory analysis. 
Will drug or biotechnology companies be able to use my sample for profit 
in future? 
No. 
How is this study being paid for? 
The study is being sponsored by a grant from the National Health and Medical Research 
Council. 
Are there any possible benefits from participation in this study? 
If you decide to participate in this research you will gain experience in research procedures 
and also some knowledge of underlying mechanisms of anxiety and exposure therapy. If 
you are enrolled in first year Psychology, you will also receive research participation credit 
of 1.5 hour for your participation. Furthermore, you will be involved in research that may 
provide a platform to better understand the mechanisms and processes involved in the 
extinction of fear, and this may ultimately lead to more efficient and effective exposure 
treatments for anxiety disorders. 
Are there any possible risks from participation in this study? 
Prior to commencement of the study you will be asked to sign consent form which will 
evidence your agreement to participate. You may feel a small amount of arousal or 
discomfort from the mild electrical stimulus. However, we expect that this arousal or 
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discomfort to be minimal as the level that is administered will have been selected by you to 
be uncomfortable but not painful. The technology used to administer this electrical 
stimulus is very safe and has been used in many previous studies with no adverse effect 
reported. There will be a researcher with you at all times, and you can discontinue the 
study at any time without penalty and it will not affect your relationship with the University 
of Tasmania or the School of Psychology.   
What if I change my mind during or after the study? 
Participation in this research is entirely voluntary. You may choose to withdraw from the 
study at any time without prejudice. Deciding to withdraw from this research at any time 
will not affect your academic standing in any way. You can also choose at this time to 
withdraw any data previously collected. Participants will be given copies of this information 
sheet and the statement of informed consent.  
What will happen to the information when this study is over? 
Your individual data will be treated confidentially, your name will be replaced by an ID 
number on all data. It will be kept in a locked cabinet or on password secured computers at 
the School of Psychology at the University of Tasmania for a period of at least five years 
(with the exception of the medical questionnaires which will be destroyed on completion of 
the study).  
How will the results of the study be published? 
Following completion of the research, the data will be published. However, no participant 
will be personally identifiable in these publications as only group data will be published. A 
summary of the results of these experiments will be available on the University of Tasmania 
School of Psychology Web page at www.scieng.utas.edu.au/psychol or will be available by 
contacting the researchers. 
What if I have questions about this study? 
The researchers will be available after the testing session to answer any questions you may 
have. If you have any questions, or would like any additional information regarding this 
research please contact, Cheryl McKay at mckaycl@utas.edu.au., or Prof Kim Felmingham 
at Kim.Felmingham@utas.edu.au. 
This study has been approved by the Tasmanian Social Sciences Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study, please 
contact the Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or email 
human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive 
complaints from research participants. Please quote ethics reference number H12496. 
 
 
Thank you for taking the time to consider this study. 
 
This information sheet is for you to keep. 
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Appendix B: Questionnaires 
B1: Medical checklist 
B2: The Depression Anxiety Stress Scale (DASS 21) 
B3: The Difficulty Emotion Regulation Scale (DERS) 
B4: The Catastrophic Cognitions Questionnaire – Modified (CCQ-M) 
B5: The Belief about Emotions Scale (BAES) 
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Appendix B1 
NAME: ___________________   DATE: _____________   PARTICIPANT ID: _______                  
GROUP:   EF   ML   MALE  CONSENT OBTAINED: ________________________ 
AGE: __________ GENDER_________________ MEDICATION: 
____________________________________ 
DATE OF MENSTRUATION: _______________   DAY OF CYCLE: _________________ 
SALIVA SAMPLE COLLECTED: ______________________ 
TIME SINCE WAKING: _____________   SMOKER: _______ PER DAY: ________  
WEIGHT: _____________ HEIGHT: _______________ BMI: ________________ 
DASS (ANX): ___________   DASS (DEP): _________ DASS (STR):_____________ 
CCQ: ___________________   STIMULUS: ____________mA 
DERS: __________________  
BAES: __________________ 
CS+: ____________________  IDENTIFIED: _________________ 
ADDITIONAL INFORMATION: 
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Appendix C 
Salivary data analysis 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
Appendix C 
Stratech Scientific APAC PTY Ltd 
Suite 5, Level 3, Mona Vale Rd 
Mona Vale, NSW, 2103 
ABN: 36 125 577 979 
 
Tel: +61 (0)2 9997 7728 
Fax:+61 (0)2 9012 0019 
http://www.stratechscientific.com.au 
 
 
 
Sample Preparation and Analysis 
 
Kim Felmingham Aug 2016 
estradiol and progesterone 
Sample collection and storage.   
Samples were stored frozen at -20°C until assay.  All samples underwent one freeze thaw 
cycle. 
Sample preparation 
On the day of assay appropriate number of samples were thawed analysed using 
commercially available kits (Salimetrics, USA) according to the manufacturers instructions.  
Thawed samples were centrifuged at 1500 x g for 15 min to collect clear saliva and this 
saliva was used without further processing for all assays.  All samples were brought to room 
temperature before adding to assay wells and all samples were analysed in duplicate. 
68 
 
 
 
Salivary Progesterone 
Introduction 
The Salimetrics progesterone assay kit is a competitive immunoassay specifically designed 
to measure salivary cortisol. It uses a specific polyclonal antibody to competitively bind 
endogenous salivary progesterone (sP) and a specified concentration of added horseradish 
peroxidase labeled progesterone (hrpP).  The degree of competition between endogenous 
and added progesterone can be calculated to measure salivary progesterone. The reaction 
can be summed as follows: 
  Ab + sP + hrpP  Ab/sP + Ab/hrpP 
By measuring the concentration of Ab/hrpP we can measure the amount of salivary 
progesterone (sP) present in the subject saliva. 
Test Principle 
A microtitre plate is coated with polyclonal antibodies to progesterone. Progesterone in 
unknown saliva samples competes with progesterone linked to horseradish peroxidase for 
the antibody binding sites. After incubation, unbound components are washed away. 
Bound progesterone peroxidase (Ab/hrpP) is measured by the reaction of the peroxidase 
enzyme on the substrate tetramethylbenzidine (TMB). This reaction produces a blue color. 
A yellow color is formed after stopping the reaction with sulfuric acid. Optical density is 
read on a standard plate reader at 450 nm. The amount of progesterone peroxidase 
detected is inversely proportional to the amount of salivary progesterone present. 
For the purpose of publications and thesis it is sufficient to state that salivary progesterone 
was measured using a commercially available ELISA assay (Salimetrics, USA) according to 
the manufacturers instructions.  
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Assay Performance 
Salivary progesterone correlates well with matched serum progesterone concentrations; r = 
0.80 (females), r = 0.87 (males). 
Assay sensitivity = 5.0 pg/mL. 
Intra assay variability (within assay)  5.4% 
Inter assay variability (between assays)  5.9% 
Salivary 17β-ESTRADIOL 
Introduction 
The Salimetrics™ estradiol kit is a competitive immunoassay specifically 
designed and validated for the quantitative measurement of salivary estradiol. 
It uses a specific polyclonal antibody to competitively bind endogenous salivary estradiol 
(sE) and a specified concentration of added horseradish peroxidase labeled progesterone 
(hrpE).  The degree of competition between endogenous and added estradiol can be 
calculated to measure salivary estradiol. The reaction can be summed as follows: 
  Ab + sE + hrpE  Ab/sE + Ab/hrpE 
 
By measuring the concentration of Ab/hrpE we can measure the amount of salivary 
estradiol (sE) present in the subject saliva. 
Test Principle 
A microtitre plate is coated with rabbit antibodies to estradiol. Estradiol in 
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standards and unknowns competes with estradiol linked to horseradish 
peroxidase for the antibody binding sites. After incubation, unbound 
components are washed away. Bound estradiol peroxidase is measured by the 
reaction of the peroxidase enzyme on the substrate tetramethylbenzidine 
(TMB). This reaction produces a blue color. A yellow color is formed after 
stopping the reaction with 2-molar sulfuric acid. Optical density is read on a 
standard plate reader at 450 nm. The amount of estradiol peroxidase detected 
is inversely proportional to the amount of estradiol present. 
For the purpose of publications and thesis it is sufficient to state that salivary estradiol was 
measured using a commercially available ELISA assay (Salimetrics, USA) according to the 
manufacturers instructions. 
Assay Performance 
Salivary estradiol correlates well with matched serum estradiol  
concentrations; r = 0.80 (females). 
Assay sensitivity = 0.1 pg/mL. 
Intra assay variability (within assay)  5.9% 
Inter assay variability (between assays)  6.4% 
Observations 
All samples ran well no observations. 
Mark Longster. 
Managing Director 
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Appendix D: SPSS Output 
 
One-way ANOVA: DASS Depression 
Tests of Between-Subjects Effects 
Dependent Variable:   DASS (Depression)   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 15.201
a
 2 7.600 .449 .641 .021 .898 .118 
Intercept 611.346 1 611.346 36.108 .000 .462 36.108 1.000 
GROUP 15.201 2 7.600 .449 .641 .021 .898 .118 
Error 711.111 42 16.931      
Total 1361.000 45       
Corrected Total 726.311 44       
 
Estimates 
Dependent Variable:   DASS (Depression)   
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Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 2.923 1.141 .620 5.226 
MALE 3.812 1.029 1.737 5.888 
ML 4.375 1.029 2.299 6.451 
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One-way ANOVA: DASS Anxiety 
Tests of Between-Subjects Effects 
Dependent Variable:   DASS (Anxiety)   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 9.078
a
 2 4.539 .164 .849 .008 .328 .074 
Intercept 869.452 1 869.452 31.440 .000 .428 31.440 1.000 
GROUP 9.078 2 4.539 .164 .849 .008 .328 .074 
Error 1161.500 42 27.655      
Total 2033.000 45       
Corrected Total 1170.578 44       
 
 
 
 
74 
 
 
 
 
Estimates 
Dependent Variable:   DASS (Anxiety)   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 5.000 1.459 2.057 7.943 
MALE 3.875 1.315 1.222 6.528 
ML 4.375 1.315 1.722 7.028 
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One-way ANOVA: DASS Stress 
Tests of Between-Subjects Effects 
Dependent Variable:   DASS (Stress)   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 58.313
a
 2 29.157 .890 .418 .041 1.780 .193 
Intercept 2273.907 1 2273.907 69.394 .000 .623 69.394 1.000 
GROUP 58.313 2 29.157 .890 .418 .041 1.780 .193 
Error 1376.264 42 32.768      
Total 3753.000 45       
Corrected Total 1434.578 44       
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Estimates 
Dependent Variable:   DASS (Stress)   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 6.615 1.588 3.411 9.819 
MALE 6.125 1.431 3.237 9.013 
ML 8.688 1.431 5.799 11.576 
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One-way ANOVA: Catastrophic Cognitions Questionnaire-Modified 
Tests of Between-Subjects Effects 
Dependent Variable:   Catastrophic Cognitions Questionnaire-M   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 944.859
a
 2 472.430 2.405 .103 .103 4.811 .459 
Intercept 141670.375 1 141670.375 721.279 .000 .945 721.279 1.000 
GROUP 944.859 2 472.430 2.405 .103 .103 4.811 .459 
Error 8249.452 42 196.416      
Total 151549.000 45       
Corrected Total 9194.311 44       
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Estimates 
Dependent Variable:   Catastrophic Cognitions Questionnaire-M   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 58.385 3.887 50.540 66.229 
MALE 50.188 3.504 43.117 57.258 
ML 60.563 3.504 53.492 67.633 
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One-way ANOVA: The Difficulty Emotion Regulation Scale 
Tests of Between-Subjects Effects 
Dependent Variable:   Diffficulty in Emotion Regulation Scale   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 1767.183
a
 2 883.591 2.791 .073 .117 5.582 .520 
Intercept 304679.816 1 304679.816 962.427 .000 .958 962.427 1.000 
GROUP 1767.183 2 883.591 2.791 .073 .117 5.582 .520 
Error 13296.129 42 316.574      
Total 318710.250 45       
Corrected Total 15063.311 44       
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Estimates 
Dependent Variable:   Diffficulty in Emotion Regulation Scale   
Male, Early Follicular (EF) Mid-Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 90.692 4.935 80.734 100.651 
MALE 82.344 4.448 73.367 91.320 
ML 75.000 4.448 66.023 83.977 
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One-way ANOVA: Age 
Tests of Between-Subjects Effects 
Dependent Variable:   Age of participant   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 42.262
a
 2 21.131 .498 .611 .023 .996 .126 
Intercept 26890.674 1 26890.674 633.454 .000 .938 633.454 1.000 
GROUP 42.262 2 21.131 .498 .611 .023 .996 .126 
Error 1782.938 42 42.451      
Total 28910.000 45       
Corrected Total 1825.200 44       
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Estimates 
Dependent Variable:   Age of participant   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 25.000 1.807 21.353 28.647 
MALE 25.437 1.629 22.150 28.725 
ML 23.250 1.629 19.963 26.537 
 
 
 
 
 
 
 
83 
 
 
 
 
One-way ANOVA: Body mass index (BMI) 
Tests of Between-Subjects Effects 
Dependent Variable:   Body Mass Index   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 25.091
a
 2 12.546 .846 .436 .039 1.693 .186 
Intercept 22797.600 1 22797.600 1538.168 .000 .973 1538.168 1.000 
GROUP 25.091 2 12.546 .846 .436 .039 1.693 .186 
Error 622.493 42 14.821      
Total 23812.940 45       
Corrected Total 647.584 44       
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Estimates 
Dependent Variable:   Body Mass Index   
Male, Early Follicular (EF) Mid-Luteal 
(ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 21.523 1.068 19.368 23.678 
MALE 23.250 .962 21.308 25.192 
ML 23.075 .962 21.133 25.017 
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One-way ANOVA: Hours awake 
Tests of Between-Subjects Effects 
Dependent Variable:   Hours since waking   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 19.068
a
 2 9.534 1.189 .314 .054 2.379 .246 
Intercept 1483.929 1 1483.929 185.118 .000 .815 185.118 1.000 
GROUP 19.068 2 9.534 1.189 .314 .054 2.379 .246 
Error 336.677 42 8.016      
Total 1823.500 45       
Corrected Total 355.744 44       
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Estimates 
Dependent Variable:   Hours since waking   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 6.654 .785 5.069 8.239 
MALE 5.625 .708 4.197 7.053 
ML 5.031 .708 3.603 6.460 
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One-way ANOVA: Stimulus (mA) 
Tests of Between-Subjects Effects 
Dependent Variable:   STIMULUS mA   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model .632
a
 2 .316 1.758 .185 .077 3.517 .348 
Intercept 178.257 1 178.257 991.358 .000 .959 991.358 1.000 
GROUP .632 2 .316 1.758 .185 .077 3.517 .348 
Error 7.552 42 .180      
Total 190.190 45       
Corrected Total 8.184 44       
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Estimates 
Dependent Variable:   STIMULUS mA   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 1.831 .118 1.593 2.068 
MALE 2.119 .106 1.905 2.333 
ML 2.050 .106 1.836 2.264 
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One-way ANOVA: Progesterone 
Tests of Between-Subjects Effects 
Dependent Variable:   Progesterone levels pg/ml   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 160626.310
a
 2 80313.155 14.764 .000 .413 29.528 .998 
Intercept 271582.226 1 271582.226 49.925 .000 .543 49.925 1.000 
GROUP 160626.310 2 80313.155 14.764 .000 .413 29.528 .998 
Error 228471.457 42 5439.797      
Total 682150.133 45       
Corrected Total 389097.767 44       
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Estimates 
Dependent Variable:   Progesterone levels pg/ml   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 38.462 20.456 -2.819 79.744 
MALE 34.608 18.439 -2.603 71.819 
ML 161.106 18.439 123.895 198.317 
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Pairwise Comparisons 
Dependent Variable:   Progesterone levels pg/ml   
(I) Male, Early Follicular (EF) Mid-
Luteal (ML) 
(J) Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
EF MALE 3.854 27.540 .999 -64.629 72.337 
ML -122.644
*
 27.540 .000 -191.127 -54.161 
MALE EF -3.854 27.540 .999 -72.337 64.629 
ML -126.498
*
 26.076 .000 -191.342 -61.654 
ML EF 122.644
*
 27.540 .000 54.161 191.127 
MALE 126.498
*
 26.076 .000 61.654 191.342 
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One-way ANOVA: Estradiol 
Tests of Between-Subjects Effects 
Dependent Variable:   Estroidal levels pg/ml   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 3.388
a
 2 1.694 3.540 .038 .144 7.080 .627 
Intercept 214.903 1 214.903 449.145 .000 .914 449.145 1.000 
GROUP 3.388 2 1.694 3.540 .038 .144 7.080 .627 
Error 20.096 42 .478      
Total 242.164 45       
Corrected Total 23.484 44       
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Estimates 
Dependent Variable:   Estroidal levels pg/ml   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 2.066 .192 1.679 2.453 
MALE 1.952 .173 1.604 2.301 
ML 2.569 .173 2.220 2.918 
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One-way ANOVA: Baseline SCL 
Tests of Between-Subjects Effects 
Dependent Variable:   Baseline SCL   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 3.159
a
 2 1.580 .079 .924 .004 .157 .061 
Intercept 2494.953 1 2494.953 124.233 .000 .747 124.233 1.000 
GROUP 3.159 2 1.580 .079 .924 .004 .157 .061 
Error 843.481 42 20.083      
Total 3383.105 45       
Corrected Total 846.640 44       
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Estimates 
Dependent Variable:   Baseline SCL   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 7.092 1.243 4.584 9.600 
MALE 7.670 1.120 5.409 9.931 
ML 7.683 1.120 5.422 9.944 
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RM ANOVA: Habituation 
Tests of Between-Subjects Effects 
Measure:   MEASURE_1   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
a
 
Intercept 136.963 1 136.963 159.150 .000 .791 159.150 1.000 
GROUP .509 2 .254 .295 .746 .014 .591 .094 
Error 36.145 42 .861      
 
Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Power
a
 
Condition Sphericity Assumed .017 1 .017 .098 .756 .002 .098 .061 
Greenhouse-Geisser .017 1.000 .017 .098 .756 .002 .098 .061 
Huynh-Feldt .017 1.000 .017 .098 .756 .002 .098 .061 
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Lower-bound .017 1.000 .017 .098 .756 .002 .098 .061 
Condition * GROUP Sphericity Assumed .576 2 .288 1.675 .200 .074 3.350 .333 
Greenhouse-Geisser .576 2.000 .288 1.675 .200 .074 3.350 .333 
Huynh-Feldt .576 2.000 .288 1.675 .200 .074 3.350 .333 
Lower-bound .576 2.000 .288 1.675 .200 .074 3.350 .333 
Error(Condition) Sphericity Assumed 7.221 42 .172      
Greenhouse-Geisser 7.221 42.000 .172      
Huynh-Feldt 7.221 42.000 .172      
Lower-bound 7.221 42.000 .172      
Trial Sphericity Assumed 5.442 3 1.814 9.899 .000 .191 29.698 .998 
Greenhouse-Geisser 5.442 2.752 1.977 9.899 .000 .191 27.247 .996 
Huynh-Feldt 5.442 3.000 1.814 9.899 .000 .191 29.698 .998 
Lower-bound 5.442 1.000 5.442 9.899 .003 .191 9.899 .867 
Trial * GROUP Sphericity Assumed .887 6 .148 .807 .567 .037 4.840 .310 
Greenhouse-Geisser .887 5.505 .161 .807 .557 .037 4.440 .295 
Huynh-Feldt .887 6.000 .148 .807 .567 .037 4.840 .310 
Lower-bound .887 2.000 .443 .807 .453 .037 1.613 .179 
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Error(Trial) Sphericity Assumed 23.088 126 .183      
Greenhouse-Geisser 23.088 115.601 .200      
Huynh-Feldt 23.088 126.000 .183      
Lower-bound 23.088 42.000 .550      
Condition * Trial Sphericity Assumed .182 3 .061 .314 .815 .007 .941 .109 
Greenhouse-Geisser .182 2.745 .066 .314 .798 .007 .861 .107 
Huynh-Feldt .182 3.000 .061 .314 .815 .007 .941 .109 
Lower-bound .182 1.000 .182 .314 .578 .007 .314 .085 
Condition * Trial * GROUP Sphericity Assumed .830 6 .138 .716 .637 .033 4.296 .276 
Greenhouse-Geisser .830 5.489 .151 .716 .625 .033 3.930 .263 
Huynh-Feldt .830 6.000 .138 .716 .637 .033 4.296 .276 
Lower-bound .830 2.000 .415 .716 .495 .033 1.432 .163 
Error(Condition*Trial) Sphericity Assumed 24.344 126 .193      
Greenhouse-Geisser 24.344 115.271 .211      
Huynh-Feldt 24.344 126.000 .193      
Lower-bound 24.344 42.000 .580      
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Estimates 
Measure:   MEASURE_1   
Trial Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .762 .060 .641 .883 
2 .719 .061 .596 .841 
3 .468 .063 .341 .595 
4 .531 .068 .394 .668 
 
Pairwise Comparisons 
Measure:   MEASURE_1   
(I) Trial (J) Trial Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
1 2 .043 .059 .978 -.121 .207 
3 .294
*
 .063 .000 .120 .469 
4 .231
*
 .069 .011 .040 .423 
2 1 -.043 .059 .978 -.207 .121 
3 .251
*
 .069 .004 .061 .441 
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4 .188
*
 .067 .045 .003 .373 
3 1 -.294
*
 .063 .000 -.469 -.120 
2 -.251
*
 .069 .004 -.441 -.061 
4 -.063 .056 .840 -.217 .091 
4 1 -.231
*
 .069 .011 -.423 -.040 
2 -.188
*
 .067 .045 -.373 -.003 
3 .063 .056 .840 -.091 .217 
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RM ANOVA: Acquisition 
Mauchly's Test of Sphericity
a
 
Measure:   MEASURE_1   
Within Subjects Effect Mauchly's W Approx. Chi-Square df Sig. 
Epsilon
b
 
Greenhouse-Geisser Huynh-Feldt Lower-bound 
Condition 1.000 .000 0 . 1.000 1.000 1.000 
Trial .965 1.439 5 .920 .976 1.000 .333 
Condition * Trial .916 3.587 5 .610 .947 1.000 .333 
 
Tests of Between-Subjects Effects 
Measure:   MEASURE_1   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
a
 
Intercept 184.841 1 184.841 160.493 .000 .793 160.493 1.000 
GROUP .004 2 .002 .002 .998 .000 .004 .050 
Error 48.371 42 1.152      
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Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Power
a
 
Condition Sphericity Assumed 3.168 1 3.168 9.145 .004 .179 9.145 .840 
Greenhouse-Geisser 3.168 1.000 3.168 9.145 .004 .179 9.145 .840 
Huynh-Feldt 3.168 1.000 3.168 9.145 .004 .179 9.145 .840 
Lower-bound 3.168 1.000 3.168 9.145 .004 .179 9.145 .840 
Condition * GROUP Sphericity Assumed .851 2 .425 1.228 .303 .055 2.456 .253 
Greenhouse-Geisser .851 2.000 .425 1.228 .303 .055 2.456 .253 
Huynh-Feldt .851 2.000 .425 1.228 .303 .055 2.456 .253 
Lower-bound .851 2.000 .425 1.228 .303 .055 2.456 .253 
Error(Condition) Sphericity Assumed 14.549 42 .346      
Greenhouse-Geisser 14.549 42.000 .346      
Huynh-Feldt 14.549 42.000 .346      
Lower-bound 14.549 42.000 .346      
Trial Sphericity Assumed .806 3 .269 .871 .458 .020 2.612 .236 
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Greenhouse-Geisser .806 2.929 .275 .871 .456 .020 2.550 .233 
Huynh-Feldt .806 3.000 .269 .871 .458 .020 2.612 .236 
Lower-bound .806 1.000 .806 .871 .356 .020 .871 .149 
Trial * GROUP Sphericity Assumed .869 6 .145 .469 .830 .022 2.815 .186 
Greenhouse-Geisser .869 5.857 .148 .469 .826 .022 2.748 .184 
Huynh-Feldt .869 6.000 .145 .469 .830 .022 2.815 .186 
Lower-bound .869 2.000 .434 .469 .629 .022 .938 .122 
Error(Trial) Sphericity Assumed 38.879 126 .309      
Greenhouse-Geisser 38.879 123.004 .316      
Huynh-Feldt 38.879 126.000 .309      
Lower-bound 38.879 42.000 .926      
Condition * Trial Sphericity Assumed .727 3 .242 1.150 .332 .027 3.451 .304 
Greenhouse-Geisser .727 2.841 .256 1.150 .331 .027 3.268 .295 
Huynh-Feldt .727 3.000 .242 1.150 .332 .027 3.451 .304 
Lower-bound .727 1.000 .727 1.150 .290 .027 1.150 .182 
Condition * Trial * GROUP Sphericity Assumed 1.214 6 .202 .961 .455 .044 5.766 .369 
Greenhouse-Geisser 1.214 5.682 .214 .961 .452 .044 5.460 .357 
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Huynh-Feldt 1.214 6.000 .202 .961 .455 .044 5.766 .369 
Lower-bound 1.214 2.000 .607 .961 .391 .044 1.922 .206 
Error(Condition*Trial) Sphericity Assumed 26.538 126 .211      
Greenhouse-Geisser 26.538 119.329 .222      
Huynh-Feldt 26.538 126.000 .211      
Lower-bound 26.538 42.000 .632      
 
Estimates 
Measure:   MEASURE_1   
Condition Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .814 .072 .668 .960 
2 .626 .056 .512 .739 
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Pairwise Comparisons  
Measure:   MEASURE_1   
(I) Condition (J) Condition Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
1 2 .189
*
 .062 .004 .063 .314 
2 1 -.189
*
 .062 .004 -.314 -.063 
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RM ANOVA: Early Extinction 
Mauchly's Test of Sphericity
a
 
Measure:   MEASURE_1   
Within Subjects Effect Mauchly's W Approx. Chi-Square df Sig. 
Epsilon
b
 
Greenhouse-Geisser Huynh-Feldt Lower-bound 
Condition 1.000 .000 0 . 1.000 1.000 1.000 
Trial .571 22.638 9 .007 .771 .878 .250 
Condition * Trial .742 12.086 9 .209 .874 1.000 .250 
 
Tests of Between-Subjects Effects 
Measure:   MEASURE_1   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
a
 
Intercept 151.433 1 151.433 106.873 .000 .718 106.873 1.000 
GROUP .938 2 .469 .331 .720 .016 .662 .099 
Error 59.512 42 1.417      
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Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Noncent. 
Parameter 
Observed 
Power
a
 
Condition Sphericity Assumed .009 1 .009 .045 .833 .001 .045 .055 
Greenhouse-Geisser .009 1.000 .009 .045 .833 .001 .045 .055 
Huynh-Feldt .009 1.000 .009 .045 .833 .001 .045 .055 
Lower-bound .009 1.000 .009 .045 .833 .001 .045 .055 
Condition * GROUP Sphericity Assumed .629 2 .315 1.650 .204 .073 3.301 .329 
Greenhouse-Geisser .629 2.000 .315 1.650 .204 .073 3.301 .329 
Huynh-Feldt .629 2.000 .315 1.650 .204 .073 3.301 .329 
Lower-bound .629 2.000 .315 1.650 .204 .073 3.301 .329 
Error(Condition) Sphericity Assumed 8.008 42 .191      
Greenhouse-Geisser 8.008 42.000 .191      
Huynh-Feldt 8.008 42.000 .191      
Lower-bound 8.008 42.000 .191      
Trial Sphericity Assumed 5.702 4 1.425 5.506 .000 .116 22.025 .974 
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Greenhouse-Geisser 5.702 3.083 1.849 5.506 .001 .116 16.975 .939 
Huynh-Feldt 5.702 3.513 1.623 5.506 .001 .116 19.346 .959 
Lower-bound 5.702 1.000 5.702 5.506 .024 .116 5.506 .630 
Trial * GROUP Sphericity Assumed .718 8 .090 .347 .946 .016 2.772 .163 
Greenhouse-Geisser .718 6.166 .116 .347 .915 .016 2.137 .147 
Huynh-Feldt .718 7.027 .102 .347 .932 .016 2.435 .155 
Lower-bound .718 2.000 .359 .347 .709 .016 .693 .102 
Error(Trial) Sphericity Assumed 43.493 168 .259      
Greenhouse-Geisser 43.493 129.485 .336      
Huynh-Feldt 43.493 147.566 .295      
Lower-bound 43.493 42.000 1.036      
Condition * Trial Sphericity Assumed 1.472 4 .368 1.510 .201 .035 6.040 .461 
Greenhouse-Geisser 1.472 3.495 .421 1.510 .208 .035 5.278 .427 
Huynh-Feldt 1.472 4.000 .368 1.510 .201 .035 6.040 .461 
Lower-bound 1.472 1.000 1.472 1.510 .226 .035 1.510 .225 
Condition * Trial * GROUP Sphericity Assumed .534 8 .067 .274 .974 .013 2.193 .136 
Greenhouse-Geisser .534 6.990 .076 .274 .963 .013 1.916 .129 
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Huynh-Feldt .534 8.000 .067 .274 .974 .013 2.193 .136 
Lower-bound .534 2.000 .267 .274 .762 .013 .548 .090 
Error(Condition*Trial) Sphericity Assumed 40.928 168 .244      
Greenhouse-Geisser 40.928 146.784 .279      
Huynh-Feldt 40.928 168.000 .244      
Lower-bound 40.928 42.000 .974      
 
Estimates 
Measure:   MEASURE_1   
Trial Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .778 .078 .621 .935 
2 .640 .083 .472 .808 
3 .498 .069 .357 .638 
4 .527 .070 .385 .669 
5 .472 .069 .333 .611 
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Pairwise Comparisons 
Measure:   MEASURE_1   
(I) Trial (J) Trial Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
1 2 .138 .083 .669 -.108 .384 
3 .280
*
 .090 .033 .014 .547 
4 .251 .092 .088 -.020 .521 
5 .306
*
 .096 .026 .023 .589 
2 1 -.138 .083 .669 -.384 .108 
3 .142 .065 .287 -.049 .334 
4 .113 .060 .494 -.064 .289 
5 .168 .078 .315 -.063 .399 
3 1 -.280
*
 .090 .033 -.547 -.014 
2 -.142 .065 .287 -.334 .049 
4 -.030 .055 1.000 -.191 .132 
5 .026 .066 1.000 -.169 .221 
4 1 -.251 .092 .088 -.521 .020 
2 -.113 .060 .494 -.289 .064 
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3 .030 .055 1.000 -.132 .191 
5 .055 .066 .994 -.138 .249 
5 1 -.306
*
 .096 .026 -.589 -.023 
2 -.168 .078 .315 -.399 .063 
3 -.026 .066 1.000 -.221 .169 
4 -.055 .066 .994 -.249 .138 
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RM ANOVA: Late Extinction 
Mauchly's Test of Sphericity
a
 
Measure:   MEASURE_1   
Within Subjects Effect Mauchly's W Approx. Chi-Square df Sig. 
Epsilon
b
 
Greenhouse-Geisser Huynh-Feldt Lower-bound 
Condition 1.000 .000 0 . 1.000 1.000 1.000 
Trial .565 23.069 9 .006 .751 .853 .250 
Condition * Trial .666 16.455 9 .058 .840 .966 .250 
 
Tests of Between-Subjects Effects 
Measure:   MEASURE_1   
Transformed Variable:   Average   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared 
Noncent. 
Parameter 
Observed 
Power
a
 
Intercept 134.083 1 134.083 96.121 .000 .696 96.121 1.000 
GROUP 1.977 2 .989 .709 .498 .033 1.417 .162 
Error 58.587 42 1.395      
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Tests of Within-Subjects Effects 
Measure:   MEASURE_1   
Source 
Type III 
Sum of 
Squares df 
Mean 
Square F Sig. Partial Eta Squared 
Noncent. 
Parameter 
Observed 
Power
a
 
Condition Sphericity 
Assumed 
.004 1 .004 .012 .914 .000 .012 .051 
Greenhouse-
Geisser 
.004 1.000 .004 .012 .914 .000 .012 .051 
Huynh-Feldt .004 1.000 .004 .012 .914 .000 .012 .051 
Lower-bound .004 1.000 .004 .012 .914 .000 .012 .051 
Condition * GROUP Sphericity 
Assumed 
.080 2 .040 .115 .892 .005 .230 .066 
Greenhouse-
Geisser 
.080 2.000 .040 .115 .892 .005 .230 .066 
Huynh-Feldt .080 2.000 .040 .115 .892 .005 .230 .066 
Lower-bound .080 2.000 .040 .115 .892 .005 .230 .066 
Error(Condition) Sphericity 
Assumed 
14.660 42 .349      
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Greenhouse-
Geisser 
14.660 42.000 .349      
Huynh-Feldt 14.660 42.000 .349      
Lower-bound 14.660 42.000 .349      
Trial Sphericity 
Assumed 
3.843 4 .961 3.679 .007 .081 14.717 .874 
Greenhouse-
Geisser 
3.843 3.002 1.280 3.679 .014 .081 11.045 .792 
Huynh-Feldt 3.843 3.413 1.126 3.679 .010 .081 12.556 .831 
Lower-bound 3.843 1.000 3.843 3.679 .062 .081 3.679 .466 
Trial * GROUP Sphericity 
Assumed 
2.722 8 .340 1.303 .245 .058 10.425 .586 
Greenhouse-
Geisser 
2.722 6.004 .453 1.303 .261 .058 7.824 .496 
Huynh-Feldt 2.722 6.826 .399 1.303 .254 .058 8.894 .535 
Lower-bound 2.722 2.000 1.361 1.303 .282 .058 2.606 .267 
Error(Trial) Sphericity 
Assumed 
43.871 168 .261      
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Greenhouse-
Geisser 
43.871 126.085 .348      
Huynh-Feldt 43.871 143.336 .306      
Lower-bound 43.871 42.000 1.045      
Condition * Trial Sphericity 
Assumed 
1.095 4 .274 1.106 .356 .026 4.424 .343 
Greenhouse-
Geisser 
1.095 3.361 .326 1.106 .352 .026 3.717 .311 
Huynh-Feldt 1.095 3.863 .283 1.106 .355 .026 4.272 .336 
Lower-bound 1.095 1.000 1.095 1.106 .299 .026 1.106 .177 
Condition * Trial * 
GROUP 
Sphericity 
Assumed 
2.334 8 .292 1.179 .314 .053 9.434 .534 
Greenhouse-
Geisser 
2.334 6.722 .347 1.179 .319 .053 7.927 .482 
Huynh-Feldt 2.334 7.726 .302 1.179 .315 .053 9.110 .524 
Lower-bound 2.334 2.000 1.167 1.179 .317 .053 2.358 .244 
Error(Condition*Trial) Sphericity 
Assumed 
41.567 168 .247      
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Greenhouse-
Geisser 
41.567 141.172 .294      
Huynh-Feldt 41.567 162.240 .256      
Lower-bound 41.567 42.000 .990      
 
Estimates 
Measure:   MEASURE_1   
Trial Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
1 .712 .065 .580 .844 
2 .492 .063 .365 .618 
3 .568 .082 .403 .732 
4 .536 .092 .349 .723 
5 .435 .063 .308 .562 
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Pairwise Comparisons 
Measure:   MEASURE_1   
(I) Trial (J) Trial Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
1 2 .220
*
 .074 .048 .001 .438 
3 .144 .101 .831 -.155 .443 
4 .175 .095 .528 -.106 .457 
5 .276
*
 .077 .009 .049 .504 
2 1 -.220
*
 .074 .048 -.438 -.001 
3 -.076 .073 .975 -.293 .141 
4 -.044 .075 1.000 -.266 .177 
5 .056 .057 .981 -.112 .225 
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3 1 -.144 .101 .831 -.443 .155 
2 .076 .073 .975 -.141 .293 
4 .031 .069 1.000 -.171 .234 
5 .132 .070 .490 -.074 .338 
4 1 -.175 .095 .528 -.457 .106 
2 .044 .075 1.000 -.177 .266 
3 -.031 .069 1.000 -.234 .171 
5 .101 .064 .724 -.087 .289 
5 1 -.276
*
 .077 .009 -.504 -.049 
2 -.056 .057 .981 -.225 .112 
3 -.132 .070 .490 -.338 .074 
4 -.101 .064 .724 -.289 .087 
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One-way ANOVA: Fear retention index 
Tests of Between-Subjects Effects 
Dependent Variable:   % Fear Recovery Index   
Source 
Type III Sum of 
Squares df Mean Square F Sig. Partial Eta Squared Noncent. Parameter Observed Power
b
 
Corrected Model 5042.727
a
 2 2521.364 4.269 .021 .169 8.539 .714 
Intercept 94437.107 1 94437.107 159.910 .000 .792 159.910 1.000 
GROUP 5042.727 2 2521.364 4.269 .021 .169 8.539 .714 
Error 24803.639 42 590.563      
Total 122110.073 45       
Corrected Total 29846.367 44       
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Estimates 
Dependent Variable:   % Fear Recovery Index   
Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
EF 57.279 6.740 43.677 70.881 
MALE 49.085 6.075 36.825 61.346 
ML 31.726 6.075 19.466 43.987 
 
Pairwise Comparisons 
Dependent Variable:   % Fear Recovery Index   
(I) Male, Early Follicular (EF) Mid-
Luteal (ML) 
(J) Male, Early Follicular (EF) Mid-
Luteal (ML) Mean Difference (I-J) Std. Error Sig.
b
 
95% Confidence Interval for Difference
b
 
Lower Bound Upper Bound 
EF MALE 8.194 9.074 .752 -14.371 30.758 
ML 25.553
*
 9.074 .022 2.989 48.117 
MALE EF -8.194 9.074 .752 -30.758 14.371 
ML 17.359 8.592 .142 -4.006 38.725 
ML EF -25.553
*
 9.074 .022 -48.117 -2.989 
MALE -17.359 8.592 .142 -38.725 4.006 
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Regression Analysis 
Model Summary
c
 
Model R R Square Adjusted R Square 
Std. Error of the 
Estimate 
Change Statistics 
R Square Change F Change df1 df2 Sig. F Change 
1 .025
a
 .001 -.023 26.33767 .001 .027 1 43 .871 
2 .184
b
 .034 -.012 26.20073 .033 1.451 1 42 .235 
 
Coefficients
a
 
Model 
Unstandardized Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence Interval for B Collinearity Statistics 
B Std. Error Beta Lower Bound Upper Bound Tolerance VIF 
1 (Constant) 43.327 12.608  3.436 .001 17.900 68.753   
Estroidal levels pg/ml .886 5.435 .025 .163 .871 -10.074 11.847 1.000 1.000 
2 (Constant) 40.358 12.782  3.157 .003 14.562 66.153   
Estroidal levels pg/ml 4.328 6.115 .121 .708 .483 -8.013 16.669 .782 1.279 
Progesterone levels pg/ml -.057 .048 -.207 -1.204 .235 -.153 .039 .782 1.279 
a. Dependent Variable: % Fear Recovery Index 
 
 
 
